<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062920" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of salivary gland cancer.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/head-and-neck/hp/salivary-gland-treatment-pdq">Salivary Gland Cancer (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000038946">salivary gland cancer</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Salivary Gland Cancer Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Salivary Gland Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000038946">salivary gland cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Salivary Gland Cancer</Title><SummarySection id="_403"><Title>Incidence and Mortality</Title><Para id="_123">Salivary gland tumors are a morphologically and clinically diverse group of neoplasms, which may present significant diagnostic and management challenges.  These tumors are rare, with an overall incidence in the Western world of approximately 2.5 cases  to 3.0 cases per 100,000 per year.<Reference refidx="1"/> Malignant salivary gland neoplasms account for  more than 0.5% of all malignancies and approximately 3% to 5% of all head and neck cancers.<Reference refidx="1"/><Reference refidx="2"/> Most patients with malignant salivary gland tumors are in the sixth or seventh decade of life.<Reference refidx="3"/><Reference refidx="4"/>  </Para></SummarySection><SummarySection id="_404"><Title>Carcinogenesis and Risk Factors</Title><Para id="_405">Although exposure to ionizing radiation has been implicated as a cause of salivary gland cancer, the etiology of most salivary gland cancers cannot be determined.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="5"/><Reference refidx="6"/> Occupations associated with an increased risk for salivary gland cancers include rubber products manufacturing, asbestos mining, plumbing, and some types of woodworking.<Reference refidx="3"/></Para></SummarySection><SummarySection id="_406"><Title>Anatomy</Title><Para id="_3">Tumors of the salivary glands comprise those in the major glands (e.g., parotid,
submandibular, and sublingual) and the minor glands (e.g., oral mucosa, palate, uvula,
floor of mouth, posterior tongue, retromolar area and peritonsillar area,
pharynx, larynx, and paranasal sinuses).<Reference refidx="2"/><Reference refidx="7"/>   Minor salivary gland lesions are most frequently seen in the oral cavity.<Reference refidx="2"/>
</Para><Para id="_419">Of salivary gland neoplasms,  more than 50% are benign, and approximately 70% to 80% of all salivary gland neoplasms originate in the parotid gland.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="8"/> The palate is the most common site of minor salivary gland tumors. The frequency of malignant lesions varies by site. Approximately 20% to 25% of parotid tumors, 35% to 40% of submandibular tumors, 50% of palate tumors, and more than 90% of sublingual gland tumors are malignant.<Reference refidx="1"/><Reference refidx="9"/></Para></SummarySection><SummarySection id="_408"><Title>Histopathology</Title><Para id="_125">Histologically, salivary gland tumors represent the most heterogenous group of tumors of any tissue in the body.<Reference refidx="10"/> Although almost 40 histologic types of epithelial tumors of the salivary glands exist, some are exceedingly rare and may be the subject of only a few case reports.<Reference refidx="1"/><Reference refidx="11"/> The most common benign major and minor salivary gland tumor is the pleomorphic adenoma, which comprises about 50% of all salivary gland tumors and 65% of parotid gland tumors.<Reference refidx="1"/> The most common malignant major and minor salivary gland tumor is the mucoepidermoid carcinoma, which comprises about 10% of all salivary gland neoplasms and approximately 35% of malignant salivary gland neoplasms.<Reference refidx="1"/> <Reference refidx="12"/> This neoplasm occurs most often in the parotid gland.<Reference refidx="2"/><Reference refidx="12"/><Reference refidx="13"/> This type and other histologic types of salivary gland neoplasms are reviewed in detail in the <SummaryRef href="CDR0000062920#_6" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Cellular Classification of Salivary Gland Treatment</SummaryRef> section of this summary.  </Para></SummarySection><SummarySection id="_409"><Title>Clinical Presentation</Title><Para id="_126">Most patients with benign tumors of the major or minor salivary glands present with painless swelling of the parotid, submandibular, or the sublingual glands. Neurological signs, such as numbness or weakness caused by nerve involvement, typically indicate a malignancy.<Reference refidx="2"/> Facial nerve weakness that is associated with a parotid  or submandibular tumor is an ominous sign. Persistent facial pain is highly suggestive of malignancy; approximately 10% to 15% of malignant parotid neoplasms present with pain.<Reference refidx="8"/><Reference refidx="14"/>  (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.) The majority of parotid tumors, both benign and malignant, however, present as an asymptomatic mass in the gland.<Reference refidx="2"/><Reference refidx="8"/> </Para></SummarySection><SummarySection id="_410"><Title>Prognostic Factors</Title><Para id="_4">Early-stage low-grade malignant salivary gland tumors are usually curable by adequate
surgical resection alone.  The prognosis is more favorable when the tumor is
in a major salivary gland; the parotid gland is most favorable, then the submandibular gland; the least favorable primary sites are the sublingual and minor salivary glands.  Large bulky tumors or high-grade tumors carry a poorer
prognosis and may best be treated by surgical resection combined with
postoperative radiation therapy.<Reference refidx="15"/>  The prognosis also depends on the following:<Reference refidx="16"/><Reference refidx="17"/> 

</Para><ItemizedList id="_211" Style="bullet"><ListItem> Gland in which
they arise.</ListItem><ListItem>Histology.</ListItem><ListItem>Grade (i.e., degree of malignancy).</ListItem><ListItem>Extent of primary tumor
(i.e., the stage).</ListItem><ListItem>Whether the tumor involves the facial nerve, has fixation to the
skin or deep structures, or has spread to lymph nodes or distant sites.</ListItem></ItemizedList></SummarySection><SummarySection id="_411"><Title>Follow-up and Survivorship</Title><Para id="_212"> Overall, clinical stage, particularly tumor size, may be the crucial factor to  determine the outcome of salivary gland cancer and may be more important than histologic grade.<Reference refidx="18"/></Para><SummarySection id="_412"><Title>Treatment management</Title><Para id="_127">Perineural invasion can also occur, particularly in high-grade adenoid
cystic carcinoma, and should be specifically identified and treated.<Reference refidx="19"/> 
Radiation therapy may increase the chance of local control and increase the survival of patients
when adequate margins cannot be achieved.<Reference refidx="20"/>[<LOERef href="CDR0000335155">Level of evidence: 3iiiDii</LOERef>] 
Unresectable or recurrent tumors may respond to chemotherapy.<Reference refidx="21"/><Reference refidx="22"/><Reference refidx="23"/>  Fast
neutron-beam radiation therapy or accelerated hyperfractionated photon-beam
schedules have been shown to be effective in the treatment of inoperable,
unresectable, and recurrent tumors.<Reference refidx="24"/><Reference refidx="25"/><Reference refidx="26"/></Para></SummarySection><SummarySection id="_413"><Title>Follow-up after treatment</Title><Para id="_128">Complications of surgical treatment for parotid neoplasms include facial nerve dysfunction and Frey syndrome also known as gustatory flushing and sweating and the auriculotemporal syndrome.<Reference refidx="8"/> Frey syndrome has been successfully treated with injections of botulinum toxin A.<Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/></Para></SummarySection></SummarySection><SummarySection id="_414"><Title>Related Summaries</Title><Para id="_415">Note:  Other PDQ summaries containing information related to salivary gland  cancer include the following:</Para><ItemizedList id="_416" Style="bullet">
     <ListItem><SummaryRef href="CDR0000062921" url="/types/head-and-neck/hp/hypopharyngeal-treatment-pdq">Hypopharyngeal Cancer Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062922" url="/types/head-and-neck/hp/laryngeal-treatment-pdq">Laryngeal Cancer Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062930" url="/types/head-and-neck/hp/lip-mouth-treatment-pdq">Lip and Oral Cavity Cancer Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062918" url="/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Nasopharyngeal Cancer Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062931" url="/types/head-and-neck/hp/paranasal-sinus-treatment-pdq">Paranasal Sinus and Nasal Cavity Cancer Treatment</SummaryRef></ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1" PMID="12363107" MedlineID="22249866">Speight PM, Barrett AW: Salivary gland tumours. Oral Dis 8 (5): 229-40, 2002.</Citation><Citation idx="2">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="3">Ellis GL, Auclair PL: Tumors of the Salivary Glands. Washington, DC : Armed Forces Institute of Pathology,  1996. Atlas of Tumor Pathology, 3.</Citation><Citation idx="4" PMID="12167424" MedlineID="22158086">Wahlberg P, Anderson H, Biörklund A, et al.: Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients. Oral Oncol 38 (7): 706-13, 2002.</Citation><Citation idx="5" PMID="7309531" MedlineID="82075333">Scanlon EF, Sener SF: Head and neck neoplasia following irradiation for benign conditions. Head Neck Surg 4 (2): 139-45, 1981 Nov-Dec.</Citation><Citation idx="6" PMID="7782698" MedlineID="95301962">van der Laan BF, Baris G, Gregor RT, et al.: Radiation-induced tumours of the head and neck. J Laryngol Otol 109 (4): 346-9, 1995.</Citation><Citation idx="7" PMID="1659242" MedlineID="92059701">Spiro RH, Thaler HT, Hicks WF, et al.: The importance of clinical staging of minor salivary gland carcinoma. Am J Surg 162 (4): 330-6, 1991.</Citation><Citation idx="8" PMID="12593546" MedlineID="22480982">Gooden E, Witterick IJ, Hacker D, et al.: Parotid gland tumours in 255 consecutive patients: Mount Sinai Hospital's quality assurance review. J Otolaryngol 31 (6): 351-4, 2002.</Citation><Citation idx="9" PMID="3788853" MedlineID="87073254">Theriault C, Fitzpatrick PJ: Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 9 (6): 510-6, 1986.</Citation><Citation idx="10" PMID="12484654" MedlineID="22372050">Brandwein MS, Ferlito A, Bradley PJ, et al.: Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 122 (7): 758-64, 2002.</Citation><Citation idx="11">Seifert G, Sobin LH: Histological Typing of Salivary Gland Tumours. 2nd ed. Berlin, Germany: Springer-Verlag, 1991.</Citation><Citation idx="12" PMID="12167584" MedlineID="22157158">Guzzo M, Andreola S, Sirizzotti G, et al.: Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol 9 (7): 688-95, 2002.</Citation><Citation idx="13" PMID="9529011" MedlineID="98187860">Goode RK, Auclair PL, Ellis GL: Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82 (7): 1217-24, 1998.</Citation><Citation idx="14" PMID="170839" MedlineID="76037903">Spiro RH, Huvos AG, Strong EW: Cancer of the parotid gland. A clinicopathologic study of 288 primary cases. Am J Surg 130 (4): 452-9, 1975.</Citation><Citation idx="15" PMID="8655366" MedlineID="96272182">Parsons JT, Mendenhall WM, Stringer SP, et al.: Management of minor salivary gland carcinomas. Int J Radiat Oncol Biol Phys 35 (3): 443-54, 1996.</Citation><Citation idx="16" PMID="10223248" MedlineID="99237759">Vander Poorten VL, Balm AJ, Hilgers FJ, et al.: The development of a prognostic score for patients with parotid carcinoma. Cancer 85 (9): 2057-67, 1999.</Citation><Citation idx="17" PMID="15287035">Terhaard CH, Lubsen H, Van der Tweel I, et al.: Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26 (8): 681-92; discussion 692-3, 2004.</Citation><Citation idx="18">Spiro RH: Factors affecting survival in salivary gland cancers. In: McGurk M, Renehan AG, eds.: Controversies in the Management of Salivary Gland Disease. Oxford, UK: Oxford University Press, 2001, pp 143-50.</Citation><Citation idx="19" PMID="8727139" MedlineID="96336677">Gormley WB, Sekhar LN, Wright DC, et al.: Management and long-term outcome of adenoid cystic carcinoma with intracranial extension: a neurosurgical perspective. Neurosurgery 38 (6): 1105-12; discussion 1112-3, 1996.</Citation><Citation idx="20" PMID="10211318" MedlineID="99227764">Hosokawa Y, Shirato H, Kagei K, et al.: Role of radiotherapy for mucoepidermoid carcinoma of salivary gland. Oral Oncol 35 (1): 105-11, 1999.</Citation><Citation idx="21" PMID="3710859" MedlineID="86223428">Borthne A, Kjellevold K, Kaalhus O, et al.: Salivary gland malignant neoplasms: treatment and prognosis. Int J Radiat Oncol Biol Phys 12 (5): 747-54, 1986.</Citation><Citation idx="22" PMID="3744850" MedlineID="86303587">Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8 (3): 177-84, 1986 Jan-Feb.</Citation><Citation idx="23" PMID="8879381" MedlineID="97033723">Licitra L, Cavina R, Grandi C, et al.: Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7 (6): 640-2, 1996.</Citation><Citation idx="24" PMID="1651301" MedlineID="91331883">Wang CC, Goodman M: Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21 (3): 569-76, 1991.</Citation><Citation idx="25" PMID="1571909" MedlineID="92240569">Buchholz TA, Laramore GE, Griffin BR, et al.: The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer 69 (11): 2779-88, 1992.</Citation><Citation idx="26" PMID="8949764" MedlineID="97107016">Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.</Citation><Citation idx="27" PMID="9403490" MedlineID="98065748">Naumann M, Zellner M, Toyka KV, et al.: Treatment of gustatory sweating with botulinum toxin. Ann Neurol 42 (6): 973-5, 1997.</Citation><Citation idx="28" PMID="10652397" MedlineID="20119454">Arad-Cohen A, Blitzer A: Botulinum toxin treatment for symptomatic Frey's syndrome. Otolaryngol Head Neck Surg 122 (2): 237-40, 2000.</Citation><Citation idx="29" PMID="11042557" MedlineID="20498865">von Lindern JJ, Niederhagen B, Bergé S, et al.: Frey syndrome: treatment with type A botulinum toxin. Cancer 89 (8): 1659-63, 2000.</Citation></ReferenceSection></SummarySection><SummarySection id="_6"><SectMetaData><SpecificDiagnosis ref="CDR0000038946">salivary gland cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Salivary Gland Cancer</Title><Para id="_129">Salivary gland neoplasms are remarkable for their histologic diversity. These neoplasms include benign and malignant tumors of epithelial, mesenchymal, and lymphoid origin. Salivary gland tumors pose a particular challenge to the surgical pathologist. Differentiating benign from malignant tumors may be difficult, primarily because of the complexity of the classification and the rarity of several entities, which may exhibit a broad spectrum of morphologic diversity in individual lesions.<Reference refidx="1"/> In some cases, hybrid lesions may be seen.<Reference refidx="2"/> The key guiding principle to establish the malignant nature of a salivary gland tumor is the demonstration of an infiltrative margin.<Reference refidx="1"/> </Para><Para id="_130">The following cellular classification scheme draws heavily from a scheme published by the Armed Forces Institute of Pathology (AFIP).<Reference refidx="3"/>  Malignant nonepithelial neoplasms are included in the scheme because these neoplasms comprise a significant proportion of salivary gland neoplasms seen in the clinical setting.  For completeness, malignant secondary tumors are also included in the scheme.</Para><Para id="_131">Where AFIP statistics regarding the incidence, or relative frequency, of particular histopathologies are cited, some bias may exist because of the AFIP methods of case accrual as a pathology reference service.  When possible, other sources are cited for incidence data. Notwithstanding the AFIP data, the incidence of a particular histopathology has been found to vary considerably depending upon the study cited. This variability in reporting may be partially caused by  the rare incidence of many salivary gland neoplasms.</Para><SummarySection id="_132"><Title>Epithelial Neoplasms</Title><Para id="_133">The clinician should be aware that several benign epithelial salivary gland neoplasms have malignant counterparts, which are shown below:<Reference refidx="3"/></Para><ItemizedList id="_134" Style="bullet"><ListItem>Pleomorphic adenoma (i.e., mixed tumor) (see <SummaryRef href="CDR0000062920#_301" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">carcinoma ex pleomorphic adenoma</SummaryRef>).</ListItem><ListItem>	Warthin tumor, also known as  papillary cystadenoma lymphomatosum.</ListItem><ListItem>	Monomorphic adenomas:<ItemizedList id="_135" Style="dash"><ListItem>Basal cell adenoma (see <SummaryRef href="CDR0000062920#_300" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">basal cell adenocarcinoma</SummaryRef>).</ListItem><ListItem>	Canalicular adenoma. </ListItem><ListItem>	Oncocytoma (see <SummaryRef href="CDR0000062920#_251" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">oncocytic carcinoma</SummaryRef>).</ListItem><ListItem>	Sebaceous adenoma. </ListItem><ListItem>	Sebaceous lymphadenoma (see <SummaryRef href="CDR0000062920#_250" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">sebaceous lymphadenocarcinoma</SummaryRef>).</ListItem></ItemizedList></ListItem><ListItem>	Myoepithelioma (see <SummaryRef href="CDR0000062920#_311" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">myoepithelial carcinoma</SummaryRef>).</ListItem><ListItem>	Cystadenoma (see <SummaryRef href="CDR0000062920#_246" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">cystadenocarcinoma</SummaryRef>).</ListItem><ListItem>	Ductal papillomas.</ListItem><ListItem>	Sialoblastoma.</ListItem></ItemizedList><Para id="_136">Histologic grading of salivary gland carcinomas is important to determine the proper treatment approach, though it is not an independent indicator of the clinical course and must be considered in the context of the clinical stage.  Clinical stage, particularly tumor size, may be the critical factor to determine the outcome of salivary gland cancer and may be more important than histologic grade.<Reference refidx="1"/> For example, stage I intermediate-grade or high-grade mucoepidermoid carcinomas can be successfully treated, whereas low-grade mucoepidermoid carcinomas that present as stage III disease may have a very aggressive clinical course.<Reference refidx="4"/></Para><Para id="_137">Grading is used primarily for mucoepidermoid carcinomas, adenocarcinomas, not otherwise specified (NOS), adenoid cystic carcinomas, and squamous cell carcinomas.<Reference refidx="1"/><Reference refidx="3"/> Various other salivary gland carcinomas can also be categorized according to histologic grade as follows:<Reference refidx="3"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/></Para><Para id="_138"><Strong>Low grade</Strong></Para><ItemizedList id="_139" Style="bullet"><ListItem><SummaryRef href="CDR0000062920#_291" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Acinic cell carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_381" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Basal cell adenocarcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_382" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Clear cell carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_383" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Cystadenocarcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_308" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Epithelial-myoepithelial carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_388" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Mucinous adenocarcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_294" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Polymorphous low-grade adenocarcinoma (PLGA)</SummaryRef>.</ListItem></ItemizedList><Para id="_141"><Strong>Low grade, intermediate grade, and high grade</Strong></Para><ItemizedList id="_142" Style="bullet"><ListItem><SummaryRef href="CDR0000062920#_297" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Adenocarcinoma, NOS</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_218" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Mucoepidermoid carcinoma</SummaryRef>.*</ListItem><ListItem><SummaryRef href="CDR0000062920#_307" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Squamous cell carcinoma</SummaryRef>.</ListItem></ItemizedList><Para id="_143"><Strong>Intermediate grade and high grade</Strong></Para><ItemizedList id="_144" Style="bullet"><ListItem><SummaryRef href="CDR0000062920#_311" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Myoepithelial carcinoma</SummaryRef>.</ListItem></ItemizedList><Para id="_145"><Strong>High grade</Strong></Para><ItemizedList id="_146" Style="bullet"><ListItem><SummaryRef href="CDR0000062920#_309" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Anaplastic small cell carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_302" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Carcinosarcoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_390" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Large cell undifferentiated carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_389" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Small cell undifferentiated carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_387" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Salivary duct carcinoma</SummaryRef>.</ListItem></ItemizedList><Para id="_147">*<Note>Some investigators consider mucoepidermoid carcinoma to be of only two grades: low grade and high grade.<Reference refidx="5"/></Note></Para><SummarySection id="_286"><OrderedList id="_287" Style="URoman"><ListTitle>Salivary gland carcinomas and mixed tumors</ListTitle><ListItem><SummaryRef href="CDR0000062920#_218" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Mucoepidermoid carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_227" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Adenoid cystic carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_231" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Adenocarcinomas</SummaryRef>.<OrderedList id="_288" Style="UAlpha"><ListItem><SummaryRef href="CDR0000062920#_291" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Acinic cell carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_294" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">PLGA</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_297" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Adenocarcinoma, NOS</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_300" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Rare adenocarcinomas</SummaryRef>.<OrderedList id="_289" Style="Arabic"><ListItem><SummaryRef href="CDR0000062920#_381" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Basal cell adenocarcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_382" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Clear cell carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_383" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Cystadenocarcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_384" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Sebaceous adenocarcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_385" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Sebaceous lymphadenocarcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_386" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Oncocytic carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_387" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Salivary duct carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_388" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Mucinous adenocarcinoma</SummaryRef>.</ListItem></OrderedList></ListItem></OrderedList></ListItem><ListItem><SummaryRef href="CDR0000062920#_256" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Malignant mixed tumors</SummaryRef>.<OrderedList id="_290" Style="UAlpha"><ListItem><SummaryRef href="CDR0000062920#_301" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Carcinoma ex pleomorphic adenoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_302" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Carcinosarcoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_303" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Metastasizing mixed tumor</SummaryRef>.</ListItem></OrderedList></ListItem><ListItem><SummaryRef href="CDR0000062920#_306" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Rare carcinomas</SummaryRef>.<OrderedList id="_304" Style="UAlpha"><ListItem><SummaryRef href="CDR0000062920#_307" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Primary squamous cell carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_308" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Epithelial-myoepithelial carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_309" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Anaplastic small cell carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_310" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Undifferentiated carcinomas</SummaryRef>.<OrderedList id="_305" Style="Arabic"><ListItem> <SummaryRef href="CDR0000062920#_389" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Small cell undifferentiated carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_390" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Large cell undifferentiated carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_391" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Lymphoepithelial carcinoma</SummaryRef>.</ListItem></OrderedList></ListItem><ListItem><SummaryRef href="CDR0000062920#_311" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Myoepithelial carcinoma</SummaryRef>.</ListItem><ListItem><SummaryRef href="CDR0000062920#_312" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">Adenosquamous carcinoma</SummaryRef>.</ListItem></OrderedList></ListItem></OrderedList><SummarySection id="_218"><Title>Mucoepidermoid carcinoma</Title><Para id="_219">Mucoepidermoid carcinoma is a malignant epithelial tumor that is composed of various proportions of mucous, epidermoid (e.g., squamous), intermediate, columnar, and clear cells and often demonstrates prominent cystic growth. It is the most common malignant neoplasm observed in the major and minor salivary glands.<Reference refidx="1"/><Reference refidx="9"/> Mucoepidermoid carcinoma represents 29% to 34% of malignant tumors originating in both major and minor salivary glands.<Reference refidx="3"/><Reference refidx="5"/><Reference refidx="10"/><Reference refidx="11"/> In two large retrospective series, 84% to 93% of cases originated in the parotid gland.<Reference refidx="12"/><Reference refidx="13"/> With regard to malignant tumors of the minor salivary glands, mucoepidermoid carcinoma shows a strong predilection for the lower lip.<Reference refidx="3"/><Reference refidx="14"/> In an AFIP review of civilian cases, the mean age of patients was 47 years, with an age range of 8 years to 92 years.<Reference refidx="3"/> Prior exposure to ionizing radiation appears to substantially increase the risk of developing malignant neoplasms of the major salivary glands, particularly mucoepidermoid carcinoma.<Reference refidx="3"/><Reference refidx="13"/></Para><Para id="_220">Most patients are asymptomatic and present with solitary, painless masses. Symptoms include pain, drainage from the ipsilateral ear, dysphagia, trismus, and facial paralysis.<Reference refidx="3"/> (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.)</Para><Para id="_221">Microscopic grading of mucoepidermoid carcinoma is important to determine the  prognosis.<Reference refidx="1"/><Reference refidx="12"/><Reference refidx="15"/> Mucoepidermoid carcinomas are graded as low grade, intermediate grade, and high grade. Grading parameters with point values include the following:</Para><ItemizedList id="_222" Style="bullet"><ListItem>Intracystic 
component (+2).</ListItem><ListItem>Neural invasion present (+2).</ListItem><ListItem>Necrosis present (+3).</ListItem><ListItem>Mitosis (≥4 per 10 high-power field  [+3]).</ListItem><ListItem>Anaplasia present (+4).</ListItem></ItemizedList><Para id="_223">Total point scores are 0 to 4 for low grade, 5 to 6 for intermediate grade, and 7 to 14 for high grade.</Para><Para id="_224">In a retrospective review of 243 cases of mucoepidermoid carcinoma of the major salivary glands, a statistically significant correlation was shown between this point-based grading system and outcome for parotid tumors but not for submandibular tumors.<Reference refidx="12"/> Another retrospective study that used this histologic grading system indicated that tumor grade correlated well with prognosis for mucoepidermoid carcinoma of the major salivary glands, excluding submandibular tumors, and minor salivary glands.<Reference refidx="13"/>   A modification of this grading system placed more emphasis on features of tumor invasion.<Reference refidx="16"/> Nonetheless, though tumor grade may be useful, stage appears to be a better indicator of prognosis.<Reference refidx="3"/><Reference refidx="16"/></Para><Para id="_225">Cytogenetically, mucoepidermoid carcinoma is characterized by a t(11;19)(q14–21;p12–13) translocation, which is occasionally the sole cytogenetic alteration.<Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/> This translocation creates a novel fusion product, MECT1-MAML2, which disrupts a Notch signaling pathway.<Reference refidx="20"/> Notch signaling plays a key role in the normal development of many tissues and cell types, through diverse effects on cellular differentiation, survival, and/or proliferation, and may be involved in a wide variety of human neoplasms.<Reference refidx="21"/></Para><Para id="_226">Rarely, mucoepidermoid carcinoma may originate within the jaws. This tumor type is known as central mucoepidermoid carcinoma.<Reference refidx="3"/> The mandibular to maxillary predilection is approximately  3:1.<Reference refidx="22"/> </Para></SummarySection><SummarySection id="_227"><Title>Adenoid cystic carcinoma</Title><Para id="_228">Adenoid cystic carcinoma, formerly known as cylindroma, is a slow growing but aggressive neoplasm with a remarkable capacity for recurrence.<Reference refidx="23"/> Morphologically, three growth patterns have been described: cribriform, or  classic pattern; tubular; and solid, or basaloid pattern. The tumors are categorized according to the predominant pattern.<Reference refidx="3"/><Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/> The cribriform pattern shows epithelial cell nests that form cylindrical patterns. The lumina of these spaces contain periodic acid-Schiff (PAS)-positive mucopolysaccharide secretions.  The tubular pattern reveals tubular structures that are lined by stratified cuboidal epithelium.  The solid pattern shows solid groups of cuboidal cells. The cribriform pattern is the most common, and the solid pattern is the least common.<Reference refidx="26"/> Solid adenoid cystic carcinoma is a high-grade lesion with reported recurrence rates of as much as  100% compared with 50% to 80% for the tubular and cribriform variants.<Reference refidx="25"/></Para><Para id="_229">In a review of its case files, the AFIP found adenoid cystic carcinoma to be the fifth most common malignant epithelial tumor of the salivary glands after mucoepidermoid carcinomas; adenocarcinomas, NOS; acinic cell carcinomas; and PLGA.<Reference refidx="3"/> Other series, however,  report adenoid cystic carcinoma to be the second most common malignant tumor with an incidence or relative frequency of approximately 20%.<Reference refidx="1"/> In the AFIP data, this neoplasm constitutes approximately 7.5% of all epithelial malignancies and 4% of all benign and malignant epithelial salivary gland tumors. The peak incidence for this tumor is reported to be in the fourth through sixth decades of life.<Reference refidx="3"/></Para><Para id="_230">This neoplasm typically develops as a slow growing swelling in the preauricular or submandibular region. Pain and facial paralysis develop frequently during the course of the disease and are likely related to the associated high incidence of nerve invasion.<Reference refidx="3"/> (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.) Regardless of histologic grade, adenoid cystic carcinomas, with their unusually slow biologic growth, tend to have a protracted course and ultimately a poor outcome, with a 10-year survival reported to be less than 50% for all grades.<Reference refidx="1"/><Reference refidx="27"/> These carcinomas typically show frequent recurrences and late distant metastases.<Reference refidx="1"/><Reference refidx="28"/> Clinical stage may be a better prognostic indicator than histologic grade.<Reference refidx="28"/><Reference refidx="29"/> In a retrospective review of 92 cases, a tumor size  larger than 4 cm was associated with an unfavorable clinical course in all cases.<Reference refidx="30"/> </Para></SummarySection><SummarySection id="_231"><Title>Adenocarcinomas</Title><SummarySection id="_291"><Title>Acinic cell carcinoma</Title><Para id="_292">Acinic cell carcinoma, also known as acinic cell adenocarcinoma, is a malignant epithelial neoplasm in which the neoplastic cells express acinar differentiation. By conventional use, the term acinic cell carcinoma is defined by cytologic differentiation towards serous acinar cells, as opposed to mucous acinar cells, whose characteristic feature is cytoplasmic periodic acid-Schiff (PAS)-positive zymogen-type secretory granules.<Reference refidx="3"/> In AFIP data of salivary gland neoplasms, acinic cell carcinoma is the third most common salivary gland epithelial neoplasm after mucoepidermoid carcinoma and adenocarcinoma, NOS.<Reference refidx="3"/> In these data, acinic cell carcinoma comprised 17% of primary malignant salivary gland tumors or about 6% of all salivary gland neoplasms; more than 80% occur in the parotid gland; women were affected more than men; and the mean age was 44 years. Other studies have reported a relative frequency of acinic cell carcinoma from 0% to 19% of malignant salivary gland neoplasms.<Reference refidx="3"/></Para><Para id="_293">Clinically, patients typically present with a slowly enlarging mass in the parotid region. Pain is a symptom in more than  33% of patients. (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.) For acinic cell carcinoma, staging is likely a better predictor of outcome than histologic grading.<Reference refidx="3"/> In a retrospective review of 90 cases, poor prognostic features included pain or fixation; gross 
invasion; and microscopic features of desmoplasia, atypia, or increased mitotic activity. Neither morphologic pattern nor cell composition was a predictive feature.<Reference refidx="31"/> </Para></SummarySection><SummarySection id="_294"><Title>PLGA</Title><Para id="_295">PLGA is a malignant epithelial tumor that is essentially limited to occurrence in minor salivary gland sites and is characterized by bland, uniform nuclear features; diverse but characteristic architecture; infiltrative growth; and perineural infiltration.<Reference refidx="3"/> In a series of 426 minor salivary gland tumors, PLGA represented 11% of all tumors and 26% of those that were malignant.<Reference refidx="32"/> In minor gland sites, PLGA is twice as frequent as adenoid cystic carcinoma, and among all benign and malignant salivary gland neoplasms, only pleomorphic adenoma and mucoepidermoid carcinoma are more common.<Reference refidx="3"/> In the AFIP case files,  more than 60% of tumors occurred in the mucosa of either the soft or hard palates, approximately 16% occurred in the buccal mucosa, and 12% occurred in the upper lip. The average age of patients is reported to be 59 years, with 70% of patients between the ages of 50 and 79 years.<Reference refidx="3"/> The female to male ratio is about 2:1, a proportion greater than for malignant salivary gland tumors in general.<Reference refidx="3"/><Reference refidx="33"/></Para><Para id="_296">PLGA typically presents as a firm, nontender swelling involving the mucosa of the hard and soft palates (i.e., it is often found at their junction), the cheek, or the upper lip. Discomfort, bleeding, telangiectasia, or ulceration of the overlying mucosa may occasionally occur.<Reference refidx="3"/> This salivary gland neoplasm typically runs a moderately indolent course. In a study of 40 cases with long-term follow-up, overall survival was 80% at 25 years.<Reference refidx="34"/> Because of  the unpredictable behavior of the tumor, some investigators consider the qualifying term,  low grade, to be misleading and instead prefer the term, polymorphous adenocarcinoma.<Reference refidx="1"/></Para></SummarySection><SummarySection id="_297"><Title>Adenocarcinoma, NOS</Title><Para id="_298">Adenocarcinoma, NOS, is a salivary gland carcinoma that shows glandular or ductal differentiation but lacks the prominence of any of the morphologic features that characterize the other, more specific carcinoma types. The diagnosis of adenocarcinoma, NOS, is essentially one of exclusion. In an AFIP review of cases, adenocarcinoma, NOS, was second only to mucoepidermoid carcinoma in frequency among malignant salivary gland neoplasms.<Reference refidx="3"/> Other series have reported an incidence of 4% to 10%.<Reference refidx="1"/> In AFIP files, the mean patient age was 58 years.<Reference refidx="3"/>  Approximately 40% and 60% of tumors occurred in the major and minor salivary glands, respectively. Among the major salivary gland tumors, 90% occurred in the parotid gland. Adenocarcinoma, NOS is graded in a similar way to extrasalivary lesions according to the degree of differentiation.<Reference refidx="1"/>  Tumor grades include low grade, intermediate grade, and high-grade categories.<Reference refidx="3"/></Para><Para id="_299">Patients with tumors in the major salivary glands typically present with solitary, painless masses.<Reference refidx="35"/> Two retrospective studies indicate that survival is better for patients with tumors of the oral cavity than for those with tumors of the parotid and submandibular glands.<Reference refidx="35"/> <Reference refidx="36"/> These studies differ regarding the prognostic significance of tumor grade.</Para></SummarySection><SummarySection id="_300"><Title>Rare adenocarcinomas</Title><SummarySection id="_381"><Title>Basal cell adenocarcinoma</Title><Para id="_242">Basal cell adenocarcinoma, also known as basaloid salivary carcinoma, carcinoma ex monomorphic adenoma, malignant basal cell adenoma, malignant basal cell tumor, and basal cell carcinoma, is an epithelial neoplasm that is cytologically similar to basal cell adenoma but is infiltrative and has a small potential for metastasis.<Reference refidx="3"/> In AFIP case files spanning almost 11 years, basal cell carcinoma comprised 1.6% of all salivary gland neoplasms and 2.9% of salivary gland malignancies.<Reference refidx="3"/> Nearly 90% of tumors occurred in the parotid gland.<Reference refidx="3"/><Reference refidx="37"/> The average age of patients is reported to be 60 years.<Reference refidx="3"/></Para><Para id="_243">Similar to most salivary gland neoplasms, swelling is typically the only sign or symptom experienced.<Reference refidx="37"/>   A sudden increase in size may occur in a few patients.<Reference refidx="38"/>  Basal cell carcinomas are low-grade carcinomas that are infiltrative, locally destructive, and tend to recur.  The carcinomas occasionally metastasize.  In a retrospective series that included  29 patients, there were recurrences in 7 patients and metastases in 3 patients.<Reference refidx="37"/>  In another retrospective review that included  72 patients, 37% of the patients experienced local recurrences.<Reference refidx="38"/> The overall prognosis for patients with this tumor is good.<Reference refidx="37"/><Reference refidx="38"/></Para></SummarySection><SummarySection id="_382"><Title>Clear cell carcinoma</Title><Para id="_244">Clear cell carcinoma, also known as clear cell adenocarcinoma, is a very rare malignant epithelial neoplasm composed of a monomorphous population of cells that have optically clear cytoplasm with standard hematoxylin and eosin stains and lack features of other specific neoplasms. Because of inconsistencies in the methods of reporting salivary gland neoplasms,  meaningful incidence rates for this tumor are difficult to derive from the literature.<Reference refidx="3"/>  Most cases involve the minor salivary glands.<Reference refidx="1"/><Reference refidx="3"/><Reference refidx="39"/><Reference refidx="40"/><Reference refidx="41"/> In the AFIP case files, the mean age of patients is approximately 58 years.<Reference refidx="3"/></Para><Para id="_245">In most patients, swelling is the only symptom. Clear cell adenocarcinoma is a low-grade neoplasm. As of 1996, the AFIP reported that no patient is known to have died as a result of this tumor.<Reference refidx="3"/></Para></SummarySection><SummarySection id="_383"><Title>Cystadenocarcinoma</Title><Para id="_246">Cystadenocarcinoma, also known as malignant papillary cystadenoma, mucus-producing adenopapillary, or  nonepidermoid, carcinoma; low-grade papillary adenocarcinoma of the palate; and papillary adenocarcinoma, is a rare malignant epithelial tumor characterized histologically by prominent cystic and, frequently, papillary growth but lacking features that characterize cystic variants of several more common salivary gland neoplasms. Cystadenocarcinoma is the malignant counterpart of cystadenoma.<Reference refidx="3"/> </Para><Para id="_247">In a review that included  57 patients, the AFIP found that men and women are affected equally; the 
average patient age was approximately  59 years; and approximately 65% of the tumors occurred in the major salivary glands, and  primarily in the parotid.<Reference refidx="3"/> Most patients present with a slowly growing asymptomatic mass. Clinically, this neoplasm is rarely associated with pain or facial paralysis. Cystadenocarcinoma is considered to be a low-grade neoplasm.<Reference refidx="3"/></Para></SummarySection><SummarySection id="_384"><Title>Sebaceous adenocarcinoma</Title><Para id="_248"> Sebaceous adenocarcinoma is a rare malignant epithelial tumor composed of islands and sheets of cells that have morphologically atypical nuclei, an infiltrative growth pattern, and focal sebaceous differentiation. This is a very rare tumor, as few cases have been reported in the literature.<Reference refidx="3"/> Almost all cases occur in the parotid gland.<Reference refidx="3"/> The average age of patients is reported to be 69 years.<Reference refidx="42"/></Para><Para id="_249">An equal number of patients present with a painless, slow-growing, asymptomatic swelling or pain. A few experience facial paralysis.<Reference refidx="3"/> Most sebaceous adenocarcinomas are probably intermediate-grade malignancies. Tumor recurs in about 33%  of cases.<Reference refidx="43"/><Reference refidx="44"/></Para></SummarySection><SummarySection id="_385"><Title>Sebaceous lymphadenocarcinoma</Title><Para id="_250">Sebaceous lymphadenocarcinoma is an extremely rare malignant tumor that represents carcinomatous transformation of sebaceous lymphadenoma. The carcinoma element may be sebaceous adenocarcinoma or some other specific or nonspecific form of salivary gland cancer.<Reference refidx="3"/>  Only three cases have been reported in the literature.<Reference refidx="43"/><Reference refidx="45"/> The three cases occurred in or around the parotid gland. All patients were in their seventh decade of life. Two of the three patients were asymptomatic. One had tenderness on palpation. Case reports suggest that this is a low-grade malignancy with a good prognosis.<Reference refidx="44"/><Reference refidx="45"/></Para></SummarySection><SummarySection id="_386"><Title>Oncocytic carcinoma</Title><Para id="_251">Oncocytic carcinoma, also known as oncocytic adenocarcinoma, is a rare, predominantly oncocytic neoplasm whose malignant nature is reflected both by its abnormal morphologic features and infiltrative growth. Oncocytic carcinoma represents less than 1% of almost 3,100 salivary gland tumors accessioned to the AFIP files during  a 10-year period.<Reference refidx="3"/> Most cases occur in the parotid gland. The average age of patients in the AFIP series was 63 years.<Reference refidx="3"/></Para><Para id="_252">Approximately 33% of the patients usually develop parotid masses that cause pain or paralysis.<Reference refidx="46"/> Oncocytic carcinoma is a high-grade carcinoma. Tumors smaller than 2 cm have a better prognosis than larger tumors.<Reference refidx="6"/></Para></SummarySection><SummarySection id="_387"><Title>Salivary duct carcinoma</Title><Para id="_253">Salivary duct carcinoma,  also known as salivary duct adenocarcinoma, is a rare, typically high-grade malignant epithelial neoplasm composed of structures that resemble expanded salivary gland ducts. A low-grade variant exists.<Reference refidx="47"/> Incidence rates vary depending upon the study cited.<Reference refidx="3"/> In the AFIP files, salivary duct carcinomas represent only 0.2% of all epithelial salivary gland neoplasms. More than 85% of cases involve the parotid gland and approximately 75% of patients are men. The peak incidence is reported to be in the seventh and eighth decades of life.<Reference refidx="3"/></Para><Para id="_254">Clinically, parotid swelling is the most common sign. Facial nerve dysfunction or paralysis occur in more than 25% of patients and may be the initial manifestation.<Reference refidx="3"/>  The high-grade variant of this neoplasm is one of the most aggressive types of salivary gland carcinoma and is typified by local invasion, lymphatic and hematogenous spread, and poor prognosis.<Reference refidx="3"/><Reference refidx="7"/>  In a retrospective review of 104 cases, 33% of patients developed local recurrence, and 46% of patients developed distant metastasis.<Reference refidx="48"/></Para></SummarySection><SummarySection id="_388"><Title>Mucinous adenocarcinoma</Title><Para id="_255">Mucinous adenocarcinoma is a rare malignant neoplasm characterized by large amounts of extracellular epithelial mucin that contains cords, nests, and solitary epithelial cells. The incidence is unknown. Limited data indicate that most, if not all, occur in the major salivary glands with the submandibular gland as the predominant site.<Reference refidx="3"/><Reference refidx="49"/> These tumors may be associated with dull pain and tenderness.<Reference refidx="3"/><Reference refidx="49"/>  This neoplasm may be considered to be low grade.<Reference refidx="3"/></Para></SummarySection></SummarySection></SummarySection><SummarySection id="_256"><Title>Malignant mixed tumors</Title><Para id="_257">The classification of malignant mixed tumors, includes three distinct clinicopathologic entities: carcinoma ex pleomorphic adenoma, carcinosarcoma, and metastasizing mixed tumor. Carcinoma ex pleomorphic adenoma constitutes the vast majority of cases, whereas carcinosarcoma, a true malignant mixed tumor, and metastasizing mixed tumor are extremely rare.<Reference refidx="3"/></Para><SummarySection id="_301"><Title>Carcinoma ex pleomorphic adenoma</Title><Para id="_258">Carcinoma ex pleomorphic adenoma,  also known as carcinoma ex mixed tumor, is a carcinoma that shows histologic evidence of arising from or in a benign pleomorphic adenoma.<Reference refidx="50"/> Diagnosis requires the identification of benign tumor in the tissue sample.<Reference refidx="51"/> The incidence or relative frequency of this tumor varies  considerably depending on the study cited.<Reference refidx="1"/> A review of material at the AFIP showed carcinoma ex pleomorphic adenoma to comprise 8.8% of all mixed tumors and 4.6% of all malignant salivary gland tumors, ranking it as the sixth most common malignant salivary gland tumor after mucoepidermoid carcinoma; adenocarcinoma, NOS; acinic cell carcinoma; polymorphous low-grade adenocarcinoma; and adenoid cystic carcinoma.<Reference refidx="3"/> The neoplasm occurs primarily in the major salivary glands.<Reference refidx="52"/></Para><Para id="_259">The most common clinical presentation is a painless mass.<Reference refidx="3"/> Approximately 33%  of patients may experience facial paralysis.<Reference refidx="53"/> Depending on the series cited, survival times vary significantly: 25% to 65% at 5 years, 24% to 50% at 10 years, 10% to 35% at 15 years, and 0% to 38% at 20 years.<Reference refidx="3"/> In addition to tumor stage, histologic grade and degree of invasion are important parameters to  determine prognosis.<Reference refidx="54"/></Para></SummarySection><SummarySection id="_302"><Title>Carcinosarcoma</Title><Para id="_260">Carcinosarcoma,  also known as true malignant mixed tumor, is a rare malignant salivary gland neoplasm that contains both carcinoma and sarcoma components. Either or both components are expressed in metastatic foci. Some carcinosarcomas develop de novo while others develop in association with benign mixed tumor. This neoplasm is rare; only eight cases exist in the AFIP case files.<Reference refidx="3"/> At one facility, only 11 cases were recorded  over a 32-year period.<Reference refidx="8"/> The majority of tumors occur in the major salivary glands.</Para><Para id="_261">Swelling, pain, nerve palsy, and ulceration have been frequent clinical findings. Carcinosarcoma is an aggressive, high-grade malignancy. In the largest series reported, which consisted of 12 cases, the average survival period was 3.6 years.<Reference refidx="8"/></Para></SummarySection><SummarySection id="_303"><Title>Metastasizing mixed tumor</Title><Para id="_262">Metastasizing mixed tumor is a very rare histologically benign salivary gland neoplasm that inexplicably metastasizes. Often a long interval occurs between the diagnosis of the primary tumor and the metastases. The histologic features are within the spectrum of features that typify pleomorphic adenoma.<Reference refidx="3"/> The majority occur in the major salivary glands. The primary neoplasm is typically a single, well-defined mass. Recurrences, which may be multiple, have been reported to occur for as many as  26 years after excision of the primary neoplasm.<Reference refidx="55"/></Para></SummarySection></SummarySection><SummarySection id="_306"><Title>Rare carcinomas</Title><SummarySection id="_307"><Title>Primary squamous cell carcinoma</Title><Para id="_265">Primary squamous cell carcinoma, also known as primary epidermoid carcinoma,  is a malignant epithelial neoplasm of the major salivary glands that is composed of squamous (i.e., epidermoid) cells. Diagnosis requires the exclusion of primary disease located in some other head and neck site; indeed, most squamous cell carcinomas of the major salivary glands represent metastatic disease.<Reference refidx="3"/> This diagnosis is not made in minor salivary glands because distinction from the more common mucosal squamous cell carcinoma is not possible.<Reference refidx="3"/>  Previous exposure to ionizing radiation appears to increase the risk for developing this neoplasm.<Reference refidx="11"/><Reference refidx="56"/> <Reference refidx="57"/> The median time between radiation therapy and diagnosis of the neoplasm is approximately 15.5 years.<Reference refidx="11"/> The reported frequency of this tumor among all major salivary gland tumors has varied from 0.9% to 4.7%.<Reference refidx="3"/><Reference refidx="10"/> In AFIP major salivary gland accessions from 1985 to 1996, primary squamous cell carcinoma comprised 2.7% of all tumors; 5.4% of malignant tumors; and 2.5% and 2.8%, respectively, of all parotid and submandibular tumors.<Reference refidx="3"/> The average age in the AFIP registry was 64 years.<Reference refidx="3"/> This neoplasm occurs in the parotid gland almost nine times more often than in the submandibular gland.<Reference refidx="3"/><Reference refidx="57"/> There is a strong male predilection.<Reference refidx="3"/><Reference refidx="11"/><Reference refidx="57"/> <Reference refidx="58"/><Reference refidx="59"/> This tumor is graded in a similar way to extrasalivary lesions according to the degree of differentiation, namely, low grade, intermediate grade, and high grade.<Reference refidx="1"/></Para><Para id="_266">Most patients present with an asymptomatic mass in the parotid region. Other symptoms may include a painful mass and facial nerve palsy.<Reference refidx="57"/> The prognosis for this neoplasm is poor. In a 30-year retrospective analysis of 50 cases of squamous cell carcinoma of the salivary glands, survival rates at 5 years and 10 years were 24% and 18%, respectively.<Reference refidx="57"/></Para></SummarySection><SummarySection id="_308"><Title>Epithelial-myoepithelial carcinoma</Title><Para id="_268">Epithelial-myoepithelial carcinoma,  also known as adenomyoepithelioma, clear cell adenoma, tubular solid adenoma, monomorphic clear cell tumor, glycogen-rich adenoma, glycogen-rich adenocarcinoma, clear cell carcinoma, and salivary duct carcinoma, is an uncommon, low-grade epithelial neoplasm composed of variable proportions of ductal and large, clear-staining, differentiated myoepithelial cells.  The tumor  comprises approximately 1% of all epithelial salivary gland neoplasms.<Reference refidx="3"/><Reference refidx="60"/> It is predominantly a tumor of the parotid gland. In the AFIP case files, the mean age of patients is about 60 years and about 60% of the patients are female.<Reference refidx="3"/></Para><Para id="_269">Localized swelling is commonly the only symptom, but occasionally patients experience facial weakness or pain.<Reference refidx="61"/><Reference refidx="62"/>  Overall, epithelial-myoepithelial carcinoma is a low-grade carcinoma that recurs frequently, has a tendency to metastasize to periparotid and cervical lymph nodes, and occasionally results in distant metastasis and death.<Reference refidx="60"/><Reference refidx="62"/><Reference refidx="63"/><Reference refidx="64"/></Para></SummarySection><SummarySection id="_309"><Title>Anaplastic small cell carcinoma</Title><Para id="_271">Anaplastic small cell carcinoma of the salivary glands was first described in 1972.<Reference refidx="65"/>  Subsequent histochemical and electron microscopic studies  have supported the neuroendocrine nature of this tumor.<Reference refidx="66"/><Reference refidx="67"/>  Microscopically, the tumor cells have oval, hyperchromatic nuclei and scant amount of cytoplasm and are organized in sheets, strands, and nests.  The mitotic rate is high. Neuroendocrine carcinomas are more frequently found in the minor salivary glands and have a better survival rate compared with small cell carcinomas of the lung.<Reference refidx="68"/> The undifferentiated counterpart of this neoplasm is the small cell undifferentiated carcinoma.   </Para></SummarySection><SummarySection id="_310"><Title>Undifferentiated carcinomas</Title><Para id="_273">Undifferentiated carcinomas of salivary glands are a group of uncommon 	malignant epithelial neoplasms that lack the specific light-microscopic 	morphologic 	features of other types of salivary gland carcinomas. These carcinomas are	histologically similar to undifferentiated carcinomas that arise in other organs and 	tissues. Accordingly, metastatic carcinoma is a primary concern in the differential 	diagnosis of these neoplasms.<Reference refidx="3"/></Para><SummarySection id="_389"><Title>Small cell undifferentiated carcinoma</Title><Para id="_274">Small cell undifferentiated carcinoma,  also known as extrapulmonary oat cell carcinoma,  is a rare, primary malignant tumor that, with conventional light microscopy, is composed of undifferentiated cells and, with ultrastructural or immunohistochemical studies, does not demonstrate neuroendocrine 
differentiation. This is the undifferentiated counterpart of anaplastic small cell carcinoma (Refer to the  <SummaryRef href="CDR0000062920#_309" url="/types/head-and-neck/hp/salivary-gland-treatment-pdq">anaplastic small cell carcinoma </SummaryRef> section of this summary.)  </Para><Para id="_275">In an AFIP review of case files, small cell carcinoma represented 1.8% of all major salivary gland malignancies; the mean age of patients was 56 years.<Reference refidx="3"/>  In 50% of the cases, patients present with an asymptomatic parotid mass of 3 months' or less duration.<Reference refidx="68"/><Reference refidx="69"/><Reference refidx="70"/> This is a high-grade neoplasm. In a retrospective review of 12 cases, a tumor size of  more than 4 cm was found to be the most important predictor of behavior. In another small retrospective series, estimated survival rates at 2 and 5 years were 70% and 46%, respectively.<Reference refidx="68"/></Para></SummarySection><SummarySection id="_390"><Title>Large cell undifferentiated carcinoma</Title><Para id="_276">Large cell undifferentiated carcinoma is a tumor in which features of acinar, ductal, epidermoid, or myoepithelial differentiation are absent under light microscopy, though occasionally, poorly formed duct–like structures are found. This neoplasm accounts for approximately 1% of all epithelial salivary gland neoplasms.<Reference refidx="3"/> <Reference refidx="53"/><Reference refidx="71"/><Reference refidx="72"/> Most of these tumors occur in the parotid gland.<Reference refidx="70"/><Reference refidx="72"/> In AFIP data, the peak incidence is in the seventh to eighth decades of life.<Reference refidx="3"/></Para><Para id="_277">Rapid growth of a parotid swelling is a common clinical presentation.<Reference refidx="59"/> This is a high-grade neoplasm that frequently metastasizes and has a poor prognosis. Neoplasms 4 cm or larger may have a particularly poor outcome.<Reference refidx="70"/><Reference refidx="72"/></Para></SummarySection><SummarySection id="_391"><Title>Lymphoepithelial carcinoma</Title><Para id="_278">Lymphoepithelial carcinoma,  also known as undifferentiated carcinoma with lymphoid stroma and carcinoma ex lymphoepithelial lesion, is an undifferentiated tumor that is associated with a dense lymphoid stroma. An exceptionally high incidence of this tumor is found in the Eskimo and Inuit populations.<Reference refidx="3"/><Reference refidx="73"/> This neoplasm has been associated with Epstein-Barr virus infection.<Reference refidx="74"/><Reference refidx="75"/> Of the occurrences, 80% are in the parotid gland.<Reference refidx="3"/></Para><Para id="_279">In addition to the presence of a parotid or submandibular mass, pain is a frequent symptom, and facial nerve palsy occurs in as many as  20% of patients.<Reference refidx="76"/> (Refer to the PDQ summary on <SummaryRef href="CDR0000062738" url="/about-cancer/treatment/side-effects/pain/pain-hp-pdq">Pain</SummaryRef> for more information.) Of the patients,   more than 40% have metastases to cervical lymph nodes at initial presentation, 20% develop local recurrences or lymph node metastases, and 20% develop distant metastases within 3 years following therapy.<Reference refidx="73"/><Reference refidx="76"/><Reference refidx="77"/><Reference refidx="78"/> </Para></SummarySection></SummarySection><SummarySection id="_311"><Title>Myoepithelial carcinoma</Title><Para id="_281">Myoepithelioma carcinoma is a rare, malignant salivary gland neoplasm in which the 	tumor cells almost exclusively manifest myoepithelial differentiation. This neoplasm 	represents the malignant counterpart of benign myoepithelioma.<Reference refidx="3"/> To date, the 	largest series reported involves 25 cases.<Reference refidx="79"/> Approximately 66% of the tumors 	occur in the parotid gland.<Reference refidx="3"/><Reference refidx="74"/> The mean age of patients is reported to be 55 	years.<Reference refidx="79"/></Para><Para id="_282">The majority of patients present with the primary complaint of a painless mass.<Reference refidx="79"/> 	This is an intermediate grade  to high-grade carcinoma.<Reference refidx="3"/><Reference refidx="79"/> Histologic grade does not 	appear to correlate well with clinical behavior; tumors with a low-grade histologic 	appearance may behave aggressively.<Reference refidx="79"/></Para></SummarySection><SummarySection id="_312"><Title>Adenosquamous carcinoma</Title><Para id="_284">Adenosquamous carcinoma is an extremely rare malignant neoplasm that 	simultaneously arises from surface mucosal epithelium and salivary gland ductal 	epithelium. The carcinoma shows histopathologic features of both squamous cell carcinoma and 	adenocarcinoma.  Only a handful of reports have discussed this tumor.<Reference refidx="3"/></Para><Para id="_285">In addition to swelling, adenosquamous carcinoma produces visible changes in the 	mucosa including erythema, ulceration, and induration. Pain frequently accompanies 	ulceration. Limited data indicate that this is a highly aggressive neoplasm with a poor 	prognosis.<Reference refidx="3"/></Para></SummarySection></SummarySection></SummarySection></SummarySection><SummarySection id="_192"><Title>Nonepithelial Neoplasms</Title><Para id="_193"><Strong>Lymphomas and benign lymphoepithelial lesion</Strong></Para><Para id="_194">Lymphomas of the major salivary glands are characteristically of the non-Hodgkin type. In an AFIP review of case files, non-Hodgkin lymphoma accounted for 16.3% of all malignant tumors that occurred in the major salivary glands; disease in the parotid gland accounted for about 80% of all cases.<Reference refidx="3"/></Para><Para id="_195">Patients with benign lymphoepithelial lesion (e.g., Mikulicz disease), which is a manifestation of the autoimmune disease, Sjögren syndrome, are at an increased risk for development of non-Hodgkin lymphoma.<Reference refidx="80"/><Reference refidx="81"/><Reference refidx="82"/><Reference refidx="83"/><Reference refidx="84"/> Benign lymphoepithelial lesion is clinically characterized by diffuse and bilateral enlargement of the salivary and lacrimal glands.<Reference refidx="23"/> Morphologically, a salivary gland lesion is composed of prominent myoepithelial islands surrounded by a lymphocytic infiltrate. Germinal centers are often present in the lymphocytic infiltrate.<Reference refidx="23"/> Immunophenotypically and genotypically, the lymphocytic infiltrate is composed of B-lymphocytes and T-lymphocytes, which are polyclonal. In 
some instances, the B-cell lymphocytic infiltrate can undergo clonal expansion and evolve into frank non-Hodgkin lymphoma. The vast majority of the non-Hodgkin lymphomas arising in a background of benign lymphoepithelial lesions are marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT).<Reference refidx="81"/><Reference refidx="82"/><Reference refidx="83"/><Reference refidx="84"/> MALT lymphomas of the salivary glands, like their counterparts in other anatomic sites, typically display relatively indolent clinical behavior.<Reference refidx="3"/><Reference refidx="85"/> </Para><Para id="_196">Primary non-MALT lymphomas of the salivary glands may also occur and appear to have a prognosis similar to those in patients who have histologically identical nodal lymphomas.<Reference refidx="86"/><Reference refidx="87"/> Unlike non-Hodgkin lymphoma, involvement of the major salivary glands by Hodgkin lymphoma is rare. Most tumors occur in the parotid gland.<Reference refidx="3"/> The most common histologic types encountered are the nodular sclerosing and lymphocyte-predominant variants.<Reference refidx="88"/><Reference refidx="89"/></Para><Para id="_197"><Strong>Mesenchymal neoplasms</Strong></Para><Para id="_198">Mesenchymal neoplasms account for 1.9% to 5% of all neoplasms that occur within the major salivary glands.<Reference refidx="90"/><Reference refidx="91"/> These cellular classifications pertain to major salivary gland tumors. Because the minor salivary glands are small and embedded within fibrous connective tissue, fat, and skeletal muscle, the origin of a mesenchymal neoplasm from stroma cannot be determined.<Reference refidx="3"/> The types of benign mesenchymal salivary gland neoplasms include hemangiomas, lipomas, and lymphangiomas. </Para><Para id="_199">Malignant mesenchymal salivary gland neoplasms include malignant schwannomas, hemangiopericytomas, malignant fibrous histiocytomas, rhabdomyosarcomas, and fibrosarcomas, among others; in the major salivary glands, these neoplasms represent approximately 0.5% of all benign and malignant salivary gland tumors and approximately 1.5% of all malignant tumors.<Reference refidx="90"/><Reference refidx="92"/><Reference refidx="93"/> Of importance is to establish a primary salivary gland origin for these tumors by excluding the possibilities of metastasis and direct extension from other sites. In addition, the diagnosis of salivary gland carcinosarcoma should be excluded.<Reference refidx="3"/> Primary salivary gland sarcomas behave like their soft tissue counterparts in which prognosis is related to sarcoma type, histologic grade, tumor size, and stage.<Reference refidx="93"/><Reference refidx="94"/> (Refer to the PDQ summary on <SummaryRef href="CDR0000062820" url="/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq">Adult Soft Tissue Sarcoma Treatment</SummaryRef> for more information.) A comprehensive review of salivary gland mesenchymal neoplasms can be found elsewhere.<Reference refidx="95"/></Para></SummarySection><SummarySection id="_200"><Title>Malignant Secondary Neoplasms</Title><Para id="_201">Malignant neoplasms whose origins lie outside the salivary glands may involve the major salivary glands by:<Reference refidx="3"/>  </Para><OrderedList id="_209" Style="Arabic"><ListItem>Direct invasion from cancers that lie adjacent to the salivary glands.</ListItem><ListItem>Hematogenous metastases from distant primary tumors. </ListItem><ListItem>Lymphatic metastases to lymph nodes within the salivary gland.</ListItem></OrderedList><Para id="_210"> Direct invasion of nonsalivary gland tumors into the major salivary glands is principally from squamous cell and basal cell carcinomas of the overlying skin.</Para><Para id="_202">Approximately 80% of metastases to the major salivary glands may be from primary tumors elsewhere in the head and neck; the remaining 20% may be from infraclavicular sites.<Reference refidx="96"/><Reference refidx="97"/> The parotid gland is the site of 80% to 90% of the metastases, and the remainder involve the submandibular gland.<Reference refidx="97"/><Reference refidx="98"/> In a decade-long AFIP experience, metastatic tumors constituted approximately 10% of malignant neoplasms in the major salivary glands, exclusive of malignant lymphomas.<Reference refidx="3"/> The majority of metastatic primary tumors to the major salivary glands are squamous cell carcinomas and melanomas from the head and neck that presumably reach the parotid gland via the lymphatic system; infraclavicular primary tumors, such as the lung, kidney, and breast, reach the salivary glands by a hematogenous route.<Reference refidx="97"/><Reference refidx="98"/><Reference refidx="99"/> The peak incidence for metastatic tumors in the salivary glands is reported to be in the seventh decade of life.<Reference refidx="3"/></Para></SummarySection><ReferenceSection><Citation idx="1" PMID="12363107" MedlineID="22249866">Speight PM, Barrett AW: Salivary gland tumours. Oral Dis 8 (5): 229-40, 2002.</Citation><Citation idx="2" PMID="8776422" MedlineID="96372607">Seifert G, Donath K: Hybrid tumours of salivary glands. Definition and classification of five rare cases. Eur J Cancer B Oral Oncol 32B (4): 251-9, 1996.</Citation><Citation idx="3">Ellis GL, Auclair PL: Tumors of the Salivary Glands. Washington, DC : Armed Forces Institute of Pathology,  1996. Atlas of Tumor Pathology, 3.</Citation><Citation idx="4">Cheuk W, Chan JKC: Salivary gland tumors. In: Fletcher CDM, ed.: Diagnostic Histopathology of Tumors. 3rd ed. London, UK: Churchill Livingstone, 2007, pp 239-326.</Citation><Citation idx="5" PMID="707726" MedlineID="79039700">Spiro RH, Huvos AG, Berk R, et al.: Mucoepidermoid carcinoma of salivary gland origin. A clinicopathologic study of 367 cases. Am J Surg 136 (4): 461-8, 1978.</Citation><Citation idx="6" PMID="3422397" MedlineID="88123571">Goode RK, Corio RL: Oncocytic adenocarcinoma of salivary glands. Oral Surg Oral Med Oral Pathol 65 (1): 61-6, 1988.</Citation><Citation idx="7" PMID="9059870" MedlineID="97213105">Guzzo M, Di Palma S, Grandi C, et al.: Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 19 (2): 126-33, 1997.</Citation><Citation idx="8" PMID="3014420" MedlineID="86258519">Stephen J, Batsakis JG, Luna MA, et al.: True malignant mixed tumors (carcinosarcoma) of salivary glands. Oral Surg Oral Med Oral Pathol 61 (6): 597-602, 1986.</Citation><Citation idx="9">Auclair PL, Ellis GL, Gnepp DR, et al.: Salivary gland neoplasms: general considerations. In: Ellis GL, Auclair PL, Gnepp DR, eds.: Surgical Pathology of the Salivary Glands. Philadelphia, Pa: Saunders, 1991, pp 135-64.</Citation><Citation idx="10" PMID="4009321" MedlineID="85236716">Eveson JW, Cawson RA: Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol 146 (1): 51-8, 1985.</Citation><Citation idx="11" PMID="6689907" MedlineID="84079177">Spitz MR, Batsakis JG: Major salivary gland carcinoma. Descriptive epidemiology and survival of 498 patients. Arch Otolaryngol 110 (1): 45-9, 1984.</Citation><Citation idx="12" PMID="9529011" MedlineID="98187860">Goode RK, Auclair PL, Ellis GL: Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82 (7): 1217-24, 1998.</Citation><Citation idx="13" PMID="12167584" MedlineID="22157158">Guzzo M, Andreola S, Sirizzotti G, et al.: Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol 9 (7): 688-95, 2002.</Citation><Citation idx="14" PMID="3359408" MedlineID="88194271">Neville BW, Damm DD, Weir JC, et al.: Labial salivary gland tumors. Cancer 61 (10): 2113-6, 1988.</Citation><Citation idx="15" PMID="1544111" MedlineID="92183066">Auclair PL, Goode RK, Ellis GL: Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer 69 (8): 2021-30, 1992.</Citation><Citation idx="16" PMID="11420454" MedlineID="21313120">Brandwein MS, Ivanov K, Wallace DI, et al.: Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 25 (7): 835-45, 2001.</Citation><Citation idx="17" PMID="8019965" MedlineID="94291048">Nordkvist A, Gustafsson H, Juberg-Ode M, et al.: Recurrent rearrangements of 11q14-22 in mucoepidermoid carcinoma. Cancer Genet Cytogenet 74 (2): 77-83, 1994.</Citation><Citation idx="18" PMID="7736438" MedlineID="95254484">Horsman DE, Berean K, Durham JS: Translocation (11;19)(q21;p13.1) in mucoepidermoid carcinoma of salivary gland. Cancer Genet Cytogenet 80 (2): 165-6, 1995.</Citation><Citation idx="19" PMID="8646736" MedlineID="96258421">El-Naggar AK, Lovell M, Killary AM, et al.: A mucoepidermoid carcinoma of minor salivary gland with t(11;19)(q21;p13.1) as the only karyotypic abnormality. Cancer Genet Cytogenet 87 (1): 29-33, 1996.</Citation><Citation idx="20" PMID="12539049" MedlineID="22447941">Tonon G, Modi S, Wu L, et al.: t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33 (2): 208-13, 2003.</Citation><Citation idx="21" PMID="12496471" MedlineID="22383595">Allenspach EJ, Maillard I, Aster JC, et al.: Notch signaling in cancer. Cancer Biol Ther 1 (5): 466-76, 2002 Sep-Oct.</Citation><Citation idx="22" PMID="1311758" MedlineID="92177126">Brookstone MS, Huvos AG: Central salivary gland tumors of the maxilla and mandible: a clinicopathologic study of 11 cases with an analysis of the literature. J Oral Maxillofac Surg 50 (3): 229-36, 1992.</Citation><Citation idx="23">Major and minor salivary glands. In: Rosai J, ed.: Ackerman's Surgical Pathology. 8th ed. St. Louis, Mo: Mosby, 1996, pp 815-56.</Citation><Citation idx="24" PMID="2173892" MedlineID="91058305">Batsakis JG, Luna MA, el-Naggar A: Histopathologic grading of salivary gland neoplasms: III. Adenoid cystic carcinomas. Ann Otol Rhinol Laryngol 99 (12): 1007-9, 1990.</Citation><Citation idx="25">Tomich CE: Adenoid cystic carcinoma. In: Ellis GL, Auclair PL, Gnepp DR, eds.: Surgical Pathology of the Salivary Glands. Philadelphia, Pa: Saunders, 1991, pp 333-49.</Citation><Citation idx="26" PMID="208752" MedlineID="78212661">Perzin KH, Gullane P, Clairmont AC: Adenoid cystic carcinomas arising in salivary glands: a correlation of histologic features and clinical course. Cancer 42 (1): 265-82, 1978.</Citation><Citation idx="27">Spiro RH: The controversial adenoid cystic carcinoma. Clinical considerations. In: McGurk M, Renehan AG, eds.: Controversies in the Management of Salivary Gland Disease. Oxford, UK: Oxford University Press, 2001, pp 207-11.</Citation><Citation idx="28" PMID="12820326" MedlineID="22704852">Friedrich RE, Bleckmann V: Adenoid cystic carcinoma of salivary and lacrimal gland origin: localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients. Anticancer Res 23 (2A): 931-40, 2003 Mar-Apr.</Citation><Citation idx="29" PMID="1334380" MedlineID="93098367">Spiro RH, Huvos AG: Stage means more than grade in adenoid cystic carcinoma. Am J Surg 164 (6): 623-8, 1992.</Citation><Citation idx="30" PMID="2160530" MedlineID="90257845">Hamper K, Lazar F, Dietel M, et al.: Prognostic factors for adenoid cystic carcinoma of the head and neck: a retrospective evaluation of 96 cases. J Oral Pathol Med 19 (3): 101-7, 1990.</Citation><Citation idx="31" PMID="1985714" MedlineID="91091740">Lewis JE, Olsen KD, Weiland LH: Acinic cell carcinoma. Clinicopathologic review. Cancer 67 (1): 172-9, 1991.</Citation><Citation idx="32" PMID="2845326" MedlineID="89015783">Waldron CA, el-Mofty SK, Gnepp DR: Tumors of the intraoral minor salivary glands: a demographic and histologic study of 426 cases. Oral Surg Oral Med Oral Pathol 66 (3): 323-33, 1988.</Citation><Citation idx="33" PMID="8108096" MedlineID="94150975">Vincent SD, Hammond HL, Finkelstein MW: Clinical and therapeutic features of polymorphous low-grade adenocarcinoma. Oral Surg Oral Med Oral Pathol 77 (1): 41-7, 1994.</Citation><Citation idx="34" PMID="11023093" MedlineID="20475930">Evans HL, Luna MA: Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol 24 (10): 1319-28, 2000.</Citation><Citation idx="35" PMID="7125074" MedlineID="83020227">Spiro RH, Huvos AG, Strong EW: Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients. Am J Surg 144 (4): 423-31, 1982.</Citation><Citation idx="36" PMID="3386387" MedlineID="88260603">Matsuba HM, Mauney M, Simpson JR, et al.: Adenocarcinomas of major and minor salivary gland origin: a histopathologic review of treatment failure patterns. Laryngoscope 98 (7): 784-8, 1988.</Citation><Citation idx="37" PMID="8952553" MedlineID="97110392">Muller S, Barnes L: Basal cell adenocarcinoma of the salivary glands. Report of seven cases and review of the literature. Cancer 78 (12): 2471-7, 1996.</Citation><Citation idx="38" PMID="2326038" MedlineID="90221503">Ellis GL, Wiscovitch JG: Basal cell adenocarcinomas of the major salivary glands. Oral Surg Oral Med Oral Pathol 69 (4): 461-9, 1990.</Citation><Citation idx="39" PMID="1706299" MedlineID="91169413">Simpson RH, Sarsfield PT, Clarke T, et al.: Clear cell carcinoma of minor salivary glands. Histopathology 17 (5): 433-8, 1990.</Citation><Citation idx="40" PMID="1717916" MedlineID="92019667">Ogawa I, Nikai H, Takata T, et al.: Clear cell tumors of minor salivary gland origin. An immunohistochemical and ultrastructural analysis. Oral Surg Oral Med Oral Pathol 72 (2): 200-7, 1991.</Citation><Citation idx="41" PMID="7506496" MedlineID="94106702">Milchgrub S, Gnepp DR, Vuitch F, et al.: Hyalinizing clear cell carcinoma of salivary gland. Am J Surg Pathol 18 (1): 74-82, 1994.</Citation><Citation idx="42">Ellis GL, Auclair PL, Gnepp DR, et al.: Other malignant epithelial neoplasms. In: Ellis GL, Auclair PL, Gnepp DR, eds.: Surgical Pathology of the Salivary Glands. Philadelphia, Pa: Saunders, 1991, pp 455-88.</Citation><Citation idx="43" PMID="6308548" MedlineID="83272674">Gnepp DR: Sebaceous neoplasms of salivary gland origin: a review. Pathol Annu 18 Pt 1: 71-102, 1983.</Citation><Citation idx="44" PMID="6704903" MedlineID="84156092">Gnepp DR, Brannon R: Sebaceous neoplasms of salivary gland origin. Report of 21 cases. Cancer 53 (10): 2155-70, 1984.</Citation><Citation idx="45" PMID="4415696" MedlineID="75014789">Linhartová A: Sebaceous glands in salivary gland tissue. Arch Pathol 98 (5): 320-4, 1974.</Citation><Citation idx="46" PMID="8445323" MedlineID="93187526">Sugimoto T, Wakizono S, Uemura T, et al.: Malignant oncocytoma of the parotid gland: a case report with an immunohistochemical and ultrastructural study. J Laryngol Otol 107 (1): 69-74, 1993.</Citation><Citation idx="47" PMID="8780532" MedlineID="96374241">Delgado R, Klimstra D, Albores-Saavedra J: Low grade salivary duct carcinoma. A distinctive variant with a low grade histology and a predominant intraductal growth pattern. Cancer 78 (5): 958-67, 1996.</Citation><Citation idx="48" PMID="8078666" MedlineID="94359695">Barnes L, Rao U, Krause J, et al.: Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature. Oral Surg Oral Med Oral Pathol 78 (1): 64-73, 1994.</Citation><Citation idx="49" PMID="2169998" MedlineID="91003896">Osaki T, Hirota J, Ohno A, et al.: Mucinous adenocarcinoma of the submandibular gland. Cancer 66 (8): 1796-801, 1990.</Citation><Citation idx="50" PMID="11839563" MedlineID="21828332">Röijer E, Nordkvist A, Ström AK, et al.: Translocation, deletion/amplification, and expression of HMGIC and MDM2 in a carcinoma ex pleomorphic adenoma. Am J Pathol 160 (2): 433-40, 2002.</Citation><Citation idx="51" PMID="192443" MedlineID="77159838">LiVolsi VA, Perzin KH: Malignant mixed tumors arising in salivary glands. I. Carcinomas arising in benign mixed tumors: a clinicopathologic study. Cancer 39 (5): 2209-30, 1977.</Citation><Citation idx="52" PMID="8380049" MedlineID="93064860">Gnepp DR: Malignant mixed tumors of the salivary glands: a review. Pathol Annu 28 Pt 1: 279-328, 1993.</Citation><Citation idx="53">Seifert G: [Diseases of the Salivary Glands: Pathology, Diagnosis, Treatment, Facial Nerve Surgery]; translated by Philip M. Stell. Stuttgart, Germany: Thieme, 1986.</Citation><Citation idx="54" PMID="12484654" MedlineID="22372050">Brandwein MS, Ferlito A, Bradley PJ, et al.: Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 122 (7): 758-64, 2002.</Citation><Citation idx="55" PMID="1384375" MedlineID="93036183">Wenig BM, Hitchcock CL, Ellis GL, et al.: Metastasizing mixed tumor of salivary glands. A clinicopathologic and flow cytometric analysis. Am J Surg Pathol 16 (9): 845-58, 1992.</Citation><Citation idx="56" PMID="889197" MedlineID="77240381">Schneider AB, Favus MJ, Stachura ME, et al.: Salivary gland neoplasms as a late consequence of head and neck irradiation. Ann Intern Med 87 (2): 160-4, 1977.</Citation><Citation idx="57" PMID="3667298" MedlineID="88032340">Shemen LJ, Huvos AG, Spiro RH: Squamous cell carcinoma of salivary gland origin. Head Neck Surg 9 (4): 235-40, 1987 Mar-Apr.</Citation><Citation idx="58" PMID="2299955" MedlineID="90135787">Sterman BM, Kraus DH, Sebek BA, et al.: Primary squamous cell carcinoma of the parotid gland. Laryngoscope 100 (2 Pt 1): 146-8, 1990.</Citation><Citation idx="59" PMID="1642829" MedlineID="92352726">Gaughan RK, Olsen KD, Lewis JE: Primary squamous cell carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 118 (8): 798-801, 1992.</Citation><Citation idx="60" PMID="1376977" MedlineID="92303904">Batsakis JG, el-Naggar AK, Luna MA: Epithelial-myoepithelial carcinoma of salivary glands. Ann Otol Rhinol Laryngol 101 (6): 540-2, 1992.</Citation><Citation idx="61" PMID="6374571" MedlineID="84220867">Daley TD, Wysocki GP, Smout MS, et al.: Epithelial-myoepithelial carcinoma of salivary glands. Oral Surg Oral Med Oral Pathol 57 (5): 512-9, 1984.</Citation><Citation idx="62" PMID="1862557" MedlineID="91320413">Collina G, Gale N, Visonà A, et al.: Epithelial-myoepithelial carcinoma of the parotid gland: a clinico-pathologic and immunohistochemical study of seven cases. Tumori 77 (3): 257-63, 1991.</Citation><Citation idx="63" PMID="2045502" MedlineID="91258583">Simpson RH, Clarke TJ, Sarsfield PT, et al.: Epithelial-myoepithelial carcinoma of salivary glands. J Clin Pathol 44 (5): 419-23, 1991.</Citation><Citation idx="64" PMID="1399576" MedlineID="93014907">Noel S, Brozna JP: Epithelial-myoepithelial carcinoma of salivary gland with metastasis to lung: report of a case and review of the literature. Head Neck 14 (5): 401-6, 1992 Sep-Oct.</Citation><Citation idx="65" PMID="4342409" MedlineID="73012867">Koss LG, Spiro RH, Hajdu S: Small cell (oat cell) carcinoma of minor salivary gland origin. Cancer 30 (3): 737-41, 1972.</Citation><Citation idx="66" PMID="1693875" MedlineID="90283815">Gnepp DR, Wick MR: Small cell carcinoma of the major salivary glands. An immunohistochemical study. Cancer 66 (1): 185-92, 1990.</Citation><Citation idx="67" PMID="9712424" MedlineID="98376269">Perez-Ordonez B, Caruana SM, Huvos AG, et al.: Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. Hum Pathol 29 (8): 826-32, 1998.</Citation><Citation idx="68" PMID="3015370" MedlineID="86271527">Gnepp DR, Corio RL, Brannon RB: Small cell carcinoma of the major salivary glands. Cancer 58 (3): 705-14, 1986.</Citation><Citation idx="69" PMID="2829946" MedlineID="88134608">Scher RL, Feldman PS, Levine PA: Small-cell carcinoma of the parotid gland with neuroendocrine features. Arch Otolaryngol Head Neck Surg 114 (3): 319-21, 1988.</Citation><Citation idx="70" PMID="2296451" MedlineID="90114932">Hui KK, Luna MA, Batsakis JG, et al.: Undifferentiated carcinomas of the major salivary glands. Oral Surg Oral Med Oral Pathol 69 (1): 76-83, 1990.</Citation><Citation idx="71" PMID="3744850" MedlineID="86303587">Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8 (3): 177-84, 1986 Jan-Feb.</Citation><Citation idx="72" PMID="1985533" MedlineID="91090356">Batsakis JG, Luna MA: Undifferentiated carcinomas of salivary glands. Ann Otol Rhinol Laryngol 100 (1): 82-4, 1991.</Citation><Citation idx="73" PMID="3294429" MedlineID="88286839">Bosch JD, Kudryk WH, Johnson GH: The malignant lymphoepithelial lesion of the salivary glands. J Otolaryngol 17 (4): 187-90, 1988.</Citation><Citation idx="74" PMID="1651284" MedlineID="91331562">Hamilton-Dutoit SJ, Therkildsen MH, Neilsen NH, et al.: Undifferentiated carcinoma of the salivary gland in Greenlandic Eskimos: demonstration of Epstein-Barr virus DNA by in situ nucleic acid hybridization. Hum Pathol 22 (8): 811-5, 1991.</Citation><Citation idx="75" PMID="8543624" MedlineID="96138185">Leung SY, Chung LP, Yuen ST, et al.: Lymphoepithelial carcinoma of the salivary gland: in situ detection of Epstein-Barr virus. J Clin Pathol 48 (11): 1022-7, 1995.</Citation><Citation idx="76" PMID="8373339" MedlineID="93384488">Borg MF, Benjamin CS, Morton RP, et al.: Malignant lympho-epithelial lesion of the salivary gland: a case report and review of the literature. Australas Radiol 37 (3): 288-91, 1993.</Citation><Citation idx="77" PMID="3759075" MedlineID="87006702">Saw D, Lau WH, Ho JH, et al.: Malignant lymphoepithelial lesion of the salivary gland. Hum Pathol 17 (9): 914-23, 1986.</Citation><Citation idx="78" PMID="2178544" MedlineID="90179001">Cleary KR, Batsakis JG: Undifferentiated carcinoma with lymphoid stroma of the major salivary glands. Ann Otol Rhinol Laryngol 99 (3 Pt 1): 236-8, 1990.</Citation><Citation idx="79" PMID="10843278" MedlineID="20300264">Savera AT, Sloman A, Huvos AG, et al.: Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. Am J Surg Pathol 24 (6): 761-74, 2000.</Citation><Citation idx="80" PMID="102228" MedlineID="79060580">Kassan SS, Thomas TL, Moutsopoulos HM, et al.: Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89 (6): 888-92, 1978.</Citation><Citation idx="81" PMID="11510008" MedlineID="21400267">Abbondanzo SL: Extranodal marginal-zone B-cell lymphoma of the salivary gland. Ann Diagn Pathol 5 (4): 246-54, 2001.</Citation><Citation idx="82" PMID="10658904" MedlineID="20122014">Ihrler S, Baretton GB, Menauer F, et al.: Sjögren's syndrome and MALT lymphomas of salivary glands: a DNA-cytometric and interphase-cytogenetic study. Mod Pathol 13 (1): 4-12, 2000.</Citation><Citation idx="83" PMID="9894474" MedlineID="99111845">Harris NL: Lymphoid proliferations of the salivary glands. Am J Clin Pathol 111 (1 Suppl 1): S94-103, 1999.</Citation><Citation idx="84" PMID="8804813" MedlineID="96397925">DiGiuseppe JA, Corio RL, Westra WH: Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol 8 (3): 232-7, 1996.</Citation><Citation idx="85" PMID="1951845" MedlineID="92059652">Harris NL: Extranodal lymphoid infiltrates and mucosa-associated lymphoid tissue (MALT). A unifying concept. Am J Surg Pathol 15 (9): 879-84, 1991.</Citation><Citation idx="86">Burke JS: Waldeyer's ring, sinonasal region, salivary gland, thyroid gland, central nervous system, and other extranodal lymphomas and lymphoid hyperplasias. In: Knowles DM, ed.: Neoplastic Hematopathology. Baltimore, Md: Williams &amp; Wilkins, 1992, pp 1047-79.</Citation><Citation idx="87" PMID="8475914" MedlineID="93235840">Salhany KE, Pietra GG: Extranodal lymphoid disorders. Am J Clin Pathol 99 (4): 472-85, 1993.</Citation><Citation idx="88" PMID="6897643" MedlineID="83133882">Schmid U, Helbron D, Lennert K: Primary malignant lymphomas localized in salivary glands. Histopathology 6 (6): 673-87, 1982.</Citation><Citation idx="89" PMID="3731025" MedlineID="86271526">Gleeson MJ, Bennett MH, Cawson RA: Lymphomas of salivary glands. Cancer 58 (3): 699-704, 1986.</Citation><Citation idx="90" PMID="3784727" MedlineID="87063174">Seifert G, Oehne H: [Mesenchymal (non-epithelial) salivary gland tumors. Analysis of 167 tumor cases of the salivary gland register] Laryngol Rhinol Otol (Stuttg) 65 (9): 485-91, 1986.</Citation><Citation idx="91">Auclair PL, Ellis GL, Gnepp DR, et al.: Salivary gland neoplasms: general considerations. In: Ellis GL, Auclair PL, Gnepp DR, eds.: Surgical Pathology of the Salivary Glands. Philadelphia, Pa: Saunders, 1991, pp 135-64.</Citation><Citation idx="92">Auclair PL, Ellis GL: Nonlymphoid sarcomas of the major salivary glands. In: Ellis GL, Auclair PL, Gnepp DR, eds.: Surgical Pathology of the Salivary Glands. Philadelphia, Pa: Saunders, 1991, pp 514-27.</Citation><Citation idx="93" PMID="1998570" MedlineID="91151647">Luna MA, Tortoledo ME, Ordóñez NG, et al.: Primary sarcomas of the major salivary glands. Arch Otolaryngol Head Neck Surg 117 (3): 302-6, 1991.</Citation><Citation idx="94" PMID="3742455" MedlineID="86298082">Auclair PL, Langloss JM, Weiss SW, et al.: Sarcomas and sarcomatoid neoplasms of the major salivary gland regions. A clinicopathologic and immunohistochemical study of 67 cases and review of the literature. Cancer 58 (6): 1305-15, 1986.</Citation><Citation idx="95">Weiss SW, Goldblum JR: Enzinger and Weiss's Soft Tissue Tumors. 4th ed. St. Louis, Mo: Mosby, 2001.</Citation><Citation idx="96" PMID="2553901" MedlineID="90039714">Cantera JM, Hernandez AV: Bilateral parotid gland metastasis as the initial presentation of a small cell lung carcinoma. J Oral Maxillofac Surg 47 (11): 1199-201, 1989.</Citation><Citation idx="97">Gnepp DR: Metastatic disease to the major salivary glands. In: Ellis GL, Auclair PL, Gnepp DR, eds.: Surgical Pathology of the Salivary Glands. Philadelphia, Pa: Saunders, 1991, pp 560-9.</Citation><Citation idx="98" PMID="3562340" MedlineID="87175185">Seifert G, Hennings K, Caselitz J: Metastatic tumors to the parotid and submandibular glands--analysis and differential diagnosis of 108 cases. Pathol Res Pract 181 (6): 684-92, 1986.</Citation><Citation idx="99" PMID="2350137" MedlineID="90274329">Batsakis JG, Bautina E: Metastases to major salivary glands. Ann Otol Rhinol Laryngol 99 (6 Pt 1): 501-3, 1990.</Citation></ReferenceSection></SummarySection><SummarySection id="_13"><SectMetaData><SpecificDiagnosis ref="CDR0000038946">salivary gland cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Salivary Gland Cancer</Title><Para id="_14">In general, tumors of the major salivary glands are staged according to size, extraparenchymal extension, lymph node involvement (in parotid tumors, whether or not the facial nerve is involved), and presence of metastases.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> 
Tumors arising in the minor salivary glands are staged according to the anatomic site of origin (e.g., oral cavity  and sinuses).     
</Para><Para id="_340">Clinical stage, particularly tumor size, may be the critical factor to  determine the outcome of salivary gland cancer and may be more important than histologic grade.<Reference refidx="5"/><Reference refidx="6"/> Diagnostic imaging studies may be used in staging.  With excellent spatial resolution and superior soft tissue contrast, magnetic resonance imaging
(MRI) offers advantages over computed tomographic scanning in the
detection and localization of head and neck tumors. Overall, MRI is the preferred modality for evaluation of suspected neoplasms of the salivary glands.<Reference refidx="7"/></Para><SummarySection id="_375"><Title>Definitions of TNM</Title><Para id="_374">The American Joint Committee on Cancer (AJCC) has designated staging by TNM
classification to define salivary gland cancer.<Reference refidx="5"/></Para><Table id="_367"><Title>Table 1.  Primary Tumor (T)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="12.65%"/><ColSpec ColName="col2" ColNum="2" ColWidth="87.34%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Major salivary glands (parotid, submandibular, and sublingual) . In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 79-86. </entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.</entry></Row></TFoot><TBody><Row><entry>TX</entry><entry>Primary tumor cannot be assessed.</entry></Row><Row><entry>T0</entry><entry>No evidence of primary tumor.</entry></Row><Row><entry>T1</entry><entry>Tumor ≤2 cm in greatest dimension without extraparenchymal extension.<Superscript>b</Superscript></entry></Row><Row><entry>T2</entry><entry>Tumor &gt;2 cm but ≤4 cm in greatest dimension without extraparenchymal extension.<Superscript>b</Superscript></entry></Row><Row><entry>T3</entry><entry>Tumor &gt;4 cm and/or tumor having extraparenchymal extension.<Superscript>b</Superscript></entry></Row><Row><entry MoreRows="1">T4a</entry><entry>Moderately advanced disease.</entry></Row><Row><entry>Tumor invades skin, mandible, ear canal, and/or facial nerve.</entry></Row><Row><entry MoreRows="1">T4b</entry><entry>Very advanced disease.</entry></Row><Row><entry>Tumor invades skull base and/or pterygoid plates and/or encases carotid artery.</entry></Row></TBody></TGroup></Table><Table id="_368"><Title>Table 2.  Regional Lymph Nodes (N)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="13.40%"/><ColSpec ColName="col2" ColNum="2" ColWidth="86.59%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Major salivary glands (parotid, submandibular, and sublingual) . In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 79-86. </entry></Row></TFoot><TBody><Row><entry>NX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>N0</entry><entry>No regional lymph node metastasis.</entry></Row><Row><entry>N1</entry><entry>Metastasis in a single ipsilateral lymph node, ≤3 cm in greatest dimension.</entry></Row><Row><entry MoreRows="2">N2</entry><entry>Metastasis in a single ipsilateral lymph node, &gt;3 cm but ≤6 cm in greatest dimension.  </entry></Row><Row><entry>Metastases in multiple ipsilateral lymph nodes, ≤6 cm  in greatest dimension.</entry></Row><Row><entry>Metastases in bilateral or contralateral lymph nodes, ≤6 cm in greatest dimension.</entry></Row><Row><entry>N2a</entry><entry>Metastasis in a single ipsilateral lymph node, &gt;3 cm but ≤6 cm in greatest dimension.</entry></Row><Row><entry>N2b</entry><entry>Metastases in multiple ipsilateral lymph nodes, ≤6 cm in greatest dimension.</entry></Row><Row><entry>N2c</entry><entry>Metastases in bilateral or contralateral lymph nodes, ≤6 cm in greatest dimension.</entry></Row><Row><entry>N3</entry><entry>Metastasis in a lymph node, &gt; 6 cm in greatest dimension.</entry></Row></TBody></TGroup></Table><Table id="_369"><Title>Table 3.  Distant Metastasis (M)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="12.87%"/><ColSpec ColName="col2" ColNum="2" ColWidth="87.12%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Major salivary glands (parotid, submandibular, and sublingual) . In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 79-86. </entry></Row></TFoot><TBody><Row><entry>M0</entry><entry>No distant metastasis.</entry></Row><Row><entry>M1</entry><entry>Distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_370"><Title>Table 4.  Anatomic Stage/Prognostic Groups<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">T</entry><entry Align="Center">N</entry><entry Align="Center">M</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Major salivary glands (parotid, submandibular, and sublingual) . In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 79-86. </entry></Row></TFoot><TBody><Row><entry>I</entry><entry>T1</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry> II</entry><entry>T2</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry MoreRows="3">III</entry><entry>T3</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T1</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry MoreRows="5">IVA</entry><entry>T4a</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T4a</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T1</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T4a</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry MoreRows="1">IVB</entry><entry>T4b</entry><entry>Any N</entry><entry>M0</entry></Row><Row><entry>Any T</entry><entry>N3</entry><entry>M0</entry></Row><Row><entry>IVC</entry><entry>Any T</entry><entry>Any N</entry><entry>M1</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1" PMID="170839" MedlineID="76037903">Spiro RH, Huvos AG, Strong EW: Cancer of the parotid gland. A clinicopathologic study of 288 primary cases. Am J Surg 130 (4): 452-9, 1975.</Citation><Citation idx="2" PMID="201357" MedlineID="78062447">Fu KK, Leibel SA, Levine ML, et al.: Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer 40 (6): 2882-90, 1977.</Citation><Citation idx="3" PMID="7260864" MedlineID="81258283">Levitt SH, McHugh RB, Gómez-Marin O, et al.: Clinical staging system for cancer of the salivary gland: a retrospective study. Cancer 47 (11): 2712-24, 1981.</Citation><Citation idx="4" PMID="1313245" MedlineID="92207447">Kuhel W, Goepfert H, Luna M, et al.: Adenoid cystic carcinoma of the palate. Arch Otolaryngol Head Neck Surg 118 (3): 243-7, 1992.</Citation><Citation idx="5">Major salivary glands (parotid, submandibular, and sublingual). In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 79-82.</Citation><Citation idx="6">Spiro RH: Factors affecting survival in salivary gland cancers. In: McGurk M, Renehan AG, eds.: Controversies in the Management of Salivary Gland Disease. Oxford, UK: Oxford University Press, 2001, pp 143-50.</Citation><Citation idx="7" PMID="12685498" MedlineID="22571565">Shah GV: MR imaging of salivary glands. Magn Reson Imaging Clin N Am 10 (4): 631-62, 2002.</Citation></ReferenceSection></SummarySection><SummarySection id="_42"><SectMetaData><SpecificDiagnosis ref="CDR0000038946">salivary gland cancer</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview</Title><Para id="_43">The minimum therapy for low-grade malignancies of the superficial portion of
the parotid gland is a superficial parotidectomy.  For all other lesions, a
total parotidectomy is often indicated.  The facial nerve or its branches
should be resected if involved by tumor; repair can be done simultaneously. 
Growing evidence suggests that postoperative radiation therapy augments
surgical resection, particularly for the high-grade neoplasms, when margins
are close or involved, when tumors are large, or when histologic evidence of lymph node metastases is present.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/>  Clinical trials, which  have been completed in the United
States and England, indicate that fast neutron-beam radiation therapy improves
disease-free survival and overall survival in patients with unresectable tumors or for patients with recurrent neoplasms.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>  Facilities with fast neutron-beam
radiation therapy  are of limited availability in the United States.  Accelerated hyperfractionated
photon-beam radiation therapy has also resulted in high rates of long-term
local regional controls.<Reference refidx="13"/><Reference refidx="14"/>  The use of chemotherapy for malignant salivary
gland tumors remains under evaluation.<Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/>
</Para><ReferenceSection><Citation idx="1">Myers EN, Suen JY, eds.: Cancer of the Head and Neck. 3rd ed. Philadelphia, Pa: Saunders, 1996.</Citation><Citation idx="2">Freund HR: Principles of Head and Neck Surgery. 2nd ed. New York, NY: Appleton-Century-Crofts, 1979.</Citation><Citation idx="3">Lore JM: An Atlas of Head and Neck Surgery. 3rd ed. Philadelphia, Pa: Saunders, 1988.</Citation><Citation idx="4">Million RR, Cassisi NJ, eds.: Management of Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia, Pa: Lippincott, 1994.</Citation><Citation idx="5">Wang CC, ed.: Radiation Therapy for Head and Neck Neoplasms. 3rd ed. New York: Wiley-Liss, 1997.</Citation><Citation idx="6">Cummings CW, Fredrickson JM, Harker LA, et al.: Otolaryngology - Head and Neck Surgery. Saint Louis, Mo: Mosby-Year Book, Inc., 1998.</Citation><Citation idx="7" PMID="9054880" MedlineID="97207587">Garden AS, el-Naggar AK, Morrison WH, et al.: Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37 (1): 79-85, 1997.</Citation><Citation idx="8" PMID="17241753">Chen AM, Granchi PJ, Garcia J, et al.: Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 67 (4): 982-7, 2007.</Citation><Citation idx="9" PMID="1571909" MedlineID="92240569">Buchholz TA, Laramore GE, Griffin BR, et al.: The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer 69 (11): 2779-88, 1992.</Citation><Citation idx="10" PMID="8949764" MedlineID="97107016">Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.</Citation><Citation idx="11" PMID="10208669">Douglas JG, Lee S, Laramore GE, et al.: Neutron radiotherapy for the treatment of locally advanced major salivary gland tumors. Head Neck 21 (3): 255-63, 1999.</Citation><Citation idx="12" PMID="10701733">Douglas JG, Laramore GE, Austin-Seymour M, et al.: Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46 (3): 551-7, 2000.</Citation><Citation idx="13" PMID="1651301" MedlineID="91331883">Wang CC, Goodman M: Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21 (3): 569-76, 1991.</Citation><Citation idx="14" PMID="12975266">Douglas JG, Koh WJ, Austin-Seymour M, et al.: Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 129 (9): 944-8, 2003.</Citation><Citation idx="15" PMID="3035459" MedlineID="87230331">Kaplan MJ, Johns ME, Cantrell RW: Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 95 (2): 165-70, 1986.</Citation><Citation idx="16" PMID="3884153" MedlineID="85151878">Eisenberger MA: Supporting evidence for an active treatment program for advanced salivary gland carcinomas. Cancer Treat Rep 69 (3): 319-21, 1985.</Citation><Citation idx="17" PMID="3744850" MedlineID="86303587">Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8 (3): 177-84, 1986 Jan-Feb.</Citation><Citation idx="18" PMID="3788853" MedlineID="87073254">Theriault C, Fitzpatrick PJ: Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 9 (6): 510-6, 1986.</Citation><Citation idx="19" PMID="8879381" MedlineID="97033723">Licitra L, Cavina R, Grandi C, et al.: Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7 (6): 640-2, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_45"><SectMetaData><SpecificDiagnosis ref="CDR0000038947">stage I salivary gland cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage I Major Salivary Gland Cancer</Title><Para id="_47">Low-grade stage I tumors of the salivary gland are curable with surgery
alone.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>  Radiation therapy may be used for tumors for which resection
involves a significant cosmetic or functional deficit or as an adjuvant to
surgery when positive margins are present.<Reference refidx="4"/>  Neutron-beam therapy is
effective in the treatment of poor-prognosis patients with malignant salivary gland
tumors.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/>
</Para><Para id="_48">High-grade stage I salivary gland tumors that are confined to the gland in
which they arise may be cured by surgery alone, though adjuvant radiation
therapy may be used, especially with the presence of  positive margins.
</Para><SummarySection id="_49"><Title>Low-grade Tumors</Title><Para id="_50"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_315" Style="Arabic"><ListItem>Surgery alone.
</ListItem><ListItem>Postoperative radiation therapy should be considered when the resection margins are positive.</ListItem></OrderedList></SummarySection><SummarySection id="_52"><Title>High-grade Tumors</Title><Para id="_53"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_100" Style="Arabic"><ListItem>Localized high-grade salivary gland tumors that are confined to the gland in
which they arise may be cured by radical surgery alone.
</ListItem><ListItem>Postoperative radiation therapy may improve local control and increase
survival rates for patients with high-grade tumors, positive surgical
margins, or perineural invasion.<Reference refidx="8"/>[<LOERef href="CDR0000335155">Level of evidence: 3iiiDii</LOERef>]<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/>
</ListItem></OrderedList><Para id="_56"><Strong>Treatment options under clinical evaluation:
</Strong></Para><ItemizedList id="_101" Style="bullet"><ListItem>Clinical trials exploring newer methods of local control are appropriate.  The role of
chemotherapy remains under evaluation, though data suggest that some salivary
gland tumors may be responsive to chemotherapy.<Reference refidx="12"/><Reference refidx="13"/> 

</ListItem></ItemizedList></SummarySection><SummarySection id="_TrialSearch_45_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_45_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38947&amp;tt=1&amp;format=2&amp;cn=1">stage I salivary gland cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_45_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="4355256" MedlineID="74007667">Byers RM, Jesse RH, Guillamondegui OM, et al.: Malignant tumors of the submaxillary gland. Am J Surg 126 (4): 458-63, 1973.</Citation><Citation idx="2">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="3" PMID="1166937" MedlineID="76037904">Woods JE, Chong GC, Beahrs OH: Experience with 1,360 primary parotid tumors. Am J Surg 130 (4): 460-2, 1975.</Citation><Citation idx="4" PMID="164132" MedlineID="75126174">Guillamondegui OM, Byers RM, Luna MA, et al.: Aggressive surgery in treatment for parotid cancer: the role of adjunctive postoperative radiotherapy. Am J Roentgenol Radium Ther Nucl Med 123 (1): 49-54, 1975.</Citation><Citation idx="5" PMID="8949764" MedlineID="97107016">Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.</Citation><Citation idx="6" PMID="10208669">Douglas JG, Lee S, Laramore GE, et al.: Neutron radiotherapy for the treatment of locally advanced major salivary gland tumors. Head Neck 21 (3): 255-63, 1999.</Citation><Citation idx="7" PMID="10701733">Douglas JG, Laramore GE, Austin-Seymour M, et al.: Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46 (3): 551-7, 2000.</Citation><Citation idx="8" PMID="10211318" MedlineID="99227764">Hosokawa Y, Shirato H, Kagei K, et al.: Role of radiotherapy for mucoepidermoid carcinoma of salivary gland. Oral Oncol 35 (1): 105-11, 1999.</Citation><Citation idx="9" PMID="9054880" MedlineID="97207587">Garden AS, el-Naggar AK, Morrison WH, et al.: Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37 (1): 79-85, 1997.</Citation><Citation idx="10" PMID="15880750">Mendenhall WM, Morris CG, Amdur RJ, et al.: Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103 (12): 2544-50, 2005.</Citation><Citation idx="11" PMID="17241753">Chen AM, Granchi PJ, Garcia J, et al.: Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 67 (4): 982-7, 2007.</Citation><Citation idx="12" PMID="3035459" MedlineID="87230331">Kaplan MJ, Johns ME, Cantrell RW: Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 95 (2): 165-70, 1986.</Citation><Citation idx="13" PMID="3884153" MedlineID="85151878">Eisenberger MA: Supporting evidence for an active treatment program for advanced salivary gland carcinomas. Cancer Treat Rep 69 (3): 319-21, 1985.</Citation></ReferenceSection></SummarySection><SummarySection id="_58"><SectMetaData><SpecificDiagnosis ref="CDR0000038948">stage II salivary gland cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage II Major Salivary Gland Cancer</Title><Para id="_60">Low-grade stage II tumors of the salivary gland may be cured with surgery
alone.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>  Radiation therapy as primary
treatment may be used for tumors for which resection involves a significant
cosmetic or functional deficit or as an adjuvant to surgery when positive
margins are present.<Reference refidx="4"/>  </Para><Para id="_61">High-grade stage II salivary gland tumors that are confined to the gland in
which they arise may be cured by surgery alone, though adjuvant radiation
therapy may be used, especially if positive margins are present.  Primary
radiation therapy may be given for tumors that are inoperable, unresectable, or
recurrent.  Fast neutron-beam radiation therapy has been shown to improve
disease-free survival and overall survival in this clinical situation.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/>
</Para><SummarySection id="_62"><Title>Low-grade Tumors</Title><Para id="_63"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_102" Style="Arabic"><ListItem>Surgery alone or with postoperative radiation therapy, if indicated, is appropriate.<Reference refidx="8"/><Reference refidx="9"/></ListItem><ListItem>Chemotherapy should be considered in special circumstances, such  as when radiation
therapy or surgery is refused.
</ListItem></OrderedList></SummarySection><SummarySection id="_66"><Title>High-grade Tumors</Title><Para id="_67"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_103" Style="Arabic"><ListItem>Localized high-grade salivary gland tumors that are confined to the gland in
which they arise may be cured by radical surgery alone.
</ListItem><ListItem>Postoperative radiation therapy may improve local control and increase
survival rates for patients with high-grade tumors, positive surgical
margins, or perineural invasion.<Reference refidx="10"/>[<LOERef href="CDR0000335155">Level of evidence: 3iiiDii</LOERef>]<Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/>
</ListItem><ListItem>Fast neutron-beam radiation therapy or accelerated hyperfractionated photon-beam
schedules reportedly are  more effective than conventional x-ray
therapy in the treatment of patients with inoperable, unresectable, or recurrent malignant
salivary gland tumors.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="14"/></ListItem></OrderedList><Para id="_71"><Strong>Treatment options under clinical evaluation:
</Strong></Para><ItemizedList id="_104" Style="bullet"><ListItem>Clinical trials exploring ways to improve local control with radiation therapy
and/or radiosensitizers are appropriate.  The role of chemotherapy is also under study.<Reference refidx="15"/><Reference refidx="16"/> </ListItem></ItemizedList></SummarySection><SummarySection id="_TrialSearch_58_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_58_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38948&amp;tt=1&amp;format=2&amp;cn=1">stage II salivary gland cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_58_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="4355256" MedlineID="74007667">Byers RM, Jesse RH, Guillamondegui OM, et al.: Malignant tumors of the submaxillary gland. Am J Surg 126 (4): 458-63, 1973.</Citation><Citation idx="2">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="3" PMID="1166937" MedlineID="76037904">Woods JE, Chong GC, Beahrs OH: Experience with 1,360 primary parotid tumors. Am J Surg 130 (4): 460-2, 1975.</Citation><Citation idx="4" PMID="164132" MedlineID="75126174">Guillamondegui OM, Byers RM, Luna MA, et al.: Aggressive surgery in treatment for parotid cancer: the role of adjunctive postoperative radiotherapy. Am J Roentgenol Radium Ther Nucl Med 123 (1): 49-54, 1975.</Citation><Citation idx="5" PMID="8949764" MedlineID="97107016">Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.</Citation><Citation idx="6" PMID="10208669">Douglas JG, Lee S, Laramore GE, et al.: Neutron radiotherapy for the treatment of locally advanced major salivary gland tumors. Head Neck 21 (3): 255-63, 1999.</Citation><Citation idx="7" PMID="10701733">Douglas JG, Laramore GE, Austin-Seymour M, et al.: Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46 (3): 551-7, 2000.</Citation><Citation idx="8" PMID="3744850" MedlineID="86303587">Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8 (3): 177-84, 1986 Jan-Feb.</Citation><Citation idx="9" PMID="3788853" MedlineID="87073254">Theriault C, Fitzpatrick PJ: Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 9 (6): 510-6, 1986.</Citation><Citation idx="10" PMID="10211318" MedlineID="99227764">Hosokawa Y, Shirato H, Kagei K, et al.: Role of radiotherapy for mucoepidermoid carcinoma of salivary gland. Oral Oncol 35 (1): 105-11, 1999.</Citation><Citation idx="11" PMID="9054880" MedlineID="97207587">Garden AS, el-Naggar AK, Morrison WH, et al.: Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37 (1): 79-85, 1997.</Citation><Citation idx="12" PMID="15880750">Mendenhall WM, Morris CG, Amdur RJ, et al.: Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103 (12): 2544-50, 2005.</Citation><Citation idx="13" PMID="17241753">Chen AM, Granchi PJ, Garcia J, et al.: Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 67 (4): 982-7, 2007.</Citation><Citation idx="14" PMID="1651301" MedlineID="91331883">Wang CC, Goodman M: Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21 (3): 569-76, 1991.</Citation><Citation idx="15" PMID="6279995" MedlineID="82172260">Suen JY, Johns ME: Chemotherapy for salivary gland cancer. Laryngoscope 92 (3): 235-9, 1982.</Citation><Citation idx="16" PMID="6754060" MedlineID="83050489">Posner MR, Ervin TJ, Weichselbaum RR, et al.: Chemotherapy of advanced salivary gland neoplasms. Cancer 50 (11): 2261-4, 1982.</Citation></ReferenceSection></SummarySection><SummarySection id="_73"><SectMetaData><SpecificDiagnosis ref="CDR0000038949">stage III salivary gland cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage III Major Salivary Gland Cancer</Title><Para id="_75">Patients with low-grade stage III tumors of the salivary gland may be cured with surgery
alone.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/>  Radiation therapy as primary treatment is not often required but
may be used for tumors for which resection involves a significant cosmetic or
functional deficit, or as an adjuvant to surgery when positive margins are
present.<Reference refidx="4"/>  Patients with low-grade tumors that have spread to lymph nodes may be cured with
resection of the primary tumor and the involved lymph nodes, with or without
radiation therapy.  Neutron-beam therapy is effective in the treatment of
patients with tumors that have spread to local lymph nodes.
</Para><Para id="_76">Patients with high-grade stage III salivary gland tumors that are confined to the gland in
which they arise may be cured by surgery alone, though adjuvant postoperative
radiation therapy may be used, especially if positive margins are present. 
Primary conventional x-ray radiation therapy may provide palliation for patients with unresectable tumors.  Fast neutron beams, however,  have been reported to
improve disease-free survival and overall survival in this clinical situation.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/> Patients with tumors that have spread to regional lymph nodes should have a regional
lymphadenectomy as part of the initial surgical procedure.  Adjuvant radiation
therapy for these tumors may reduce the local recurrence rate.
</Para><SummarySection id="_77"><Title>Low-grade Tumors</Title><Para id="_78"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_105" Style="Arabic"><ListItem>Surgery alone or with postoperative radiation therapy, if  indicated, is appropriate.
</ListItem><ListItem>Chemotherapy should be considered in special circumstances, such as when radiation
or surgery is refused or when tumors are recurrent or nonresponsive.</ListItem></OrderedList><Para id="_81"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><ItemizedList id="_106" Style="bullet"><ListItem>Data in which fast neutron-beam radiation therapy has been used have indicated superior results when
compared with conventional radiation therapy using x-rays.  The role of
chemotherapy is under evaluation.<Reference refidx="5"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/></ListItem></ItemizedList></SummarySection><SummarySection id="_83"><Title>High-grade Tumors</Title><Para id="_84"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_107" Style="Arabic"><ListItem>Patients with localized high-grade salivary gland tumors that are confined to the gland in
which they arise may be cured by radical surgery alone.<Reference refidx="11"/><Reference refidx="12"/>
</ListItem><ListItem>Postoperative radiation therapy may improve  local control and increase
survival rates for patients with high-grade tumors, positive surgical
margins, or perineural invasion.<Reference refidx="13"/>[<LOERef href="CDR0000335155">Level of evidence: 3iiiDii</LOERef>]<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/>
</ListItem><ListItem>Fast neutron-beam radiation therapy or accelerated hyperfractionated photon-beam
schedules have been reported to be more effective than conventional x-ray
therapy in the treatment of patients with inoperable, unresectable, or recurrent malignant
salivary gland tumors.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="17"/>
</ListItem></OrderedList><Para id="_88"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><ItemizedList id="_108" Style="bullet"><ListItem>Clinical trials exploring ways to improve local control with radiation therapy
and/or radiosensitizers and with chemotherapy are under evaluation.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="18"/><Reference refidx="19"/> </ListItem></ItemizedList></SummarySection><SummarySection id="_TrialSearch_73_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_73_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38949&amp;tt=1&amp;format=2&amp;cn=1">stage III salivary gland cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_73_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="4355256" MedlineID="74007667">Byers RM, Jesse RH, Guillamondegui OM, et al.: Malignant tumors of the submaxillary gland. Am J Surg 126 (4): 458-63, 1973.</Citation><Citation idx="2">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="3" PMID="1166937" MedlineID="76037904">Woods JE, Chong GC, Beahrs OH: Experience with 1,360 primary parotid tumors. Am J Surg 130 (4): 460-2, 1975.</Citation><Citation idx="4" PMID="164132" MedlineID="75126174">Guillamondegui OM, Byers RM, Luna MA, et al.: Aggressive surgery in treatment for parotid cancer: the role of adjunctive postoperative radiotherapy. Am J Roentgenol Radium Ther Nucl Med 123 (1): 49-54, 1975.</Citation><Citation idx="5" PMID="8949764" MedlineID="97107016">Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.</Citation><Citation idx="6" PMID="10208669">Douglas JG, Lee S, Laramore GE, et al.: Neutron radiotherapy for the treatment of locally advanced major salivary gland tumors. Head Neck 21 (3): 255-63, 1999.</Citation><Citation idx="7" PMID="10701733">Douglas JG, Laramore GE, Austin-Seymour M, et al.: Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46 (3): 551-7, 2000.</Citation><Citation idx="8" PMID="3035459" MedlineID="87230331">Kaplan MJ, Johns ME, Cantrell RW: Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg 95 (2): 165-70, 1986.</Citation><Citation idx="9" PMID="3884153" MedlineID="85151878">Eisenberger MA: Supporting evidence for an active treatment program for advanced salivary gland carcinomas. Cancer Treat Rep 69 (3): 319-21, 1985.</Citation><Citation idx="10" PMID="3114186" MedlineID="87307600">Catterall M, Errington RD: The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy. Int J Radiat Oncol Biol Phys 13 (9): 1313-8, 1987.</Citation><Citation idx="11" PMID="3744850" MedlineID="86303587">Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8 (3): 177-84, 1986 Jan-Feb.</Citation><Citation idx="12" PMID="3788853" MedlineID="87073254">Theriault C, Fitzpatrick PJ: Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 9 (6): 510-6, 1986.</Citation><Citation idx="13" PMID="10211318" MedlineID="99227764">Hosokawa Y, Shirato H, Kagei K, et al.: Role of radiotherapy for mucoepidermoid carcinoma of salivary gland. Oral Oncol 35 (1): 105-11, 1999.</Citation><Citation idx="14" PMID="9054880" MedlineID="97207587">Garden AS, el-Naggar AK, Morrison WH, et al.: Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Biol Phys 37 (1): 79-85, 1997.</Citation><Citation idx="15" PMID="15880750">Mendenhall WM, Morris CG, Amdur RJ, et al.: Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 103 (12): 2544-50, 2005.</Citation><Citation idx="16" PMID="17241753">Chen AM, Granchi PJ, Garcia J, et al.: Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 67 (4): 982-7, 2007.</Citation><Citation idx="17" PMID="1651301" MedlineID="91331883">Wang CC, Goodman M: Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21 (3): 569-76, 1991.</Citation><Citation idx="18" PMID="6279995" MedlineID="82172260">Suen JY, Johns ME: Chemotherapy for salivary gland cancer. Laryngoscope 92 (3): 235-9, 1982.</Citation><Citation idx="19" PMID="6754060" MedlineID="83050489">Posner MR, Ervin TJ, Weichselbaum RR, et al.: Chemotherapy of advanced salivary gland neoplasms. Cancer 50 (11): 2261-4, 1982.</Citation></ReferenceSection></SummarySection><SummarySection id="_90"><SectMetaData><SpecificDiagnosis ref="CDR0000038950">stage IV salivary gland cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage IV Major Salivary Gland Cancer</Title><Para id="_91">Standard therapy for patients with tumors that have spread to distant sites is not curative.
</Para><Para id="_330"><Strong>Standard treatment options:
</Strong></Para><ItemizedList id="_314" Style="bullet"><ListItem>Fast neutron-beam radiation therapy or accelerated hyperfractionated photon-beam
schedules have been reported to be more effective than conventional x-ray
therapy in the treatment of patients with  inoperable, unresectable, or recurrent malignant
salivary gland tumors.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/></ListItem></ItemizedList><Para id="_94"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><ItemizedList id="_110" Style="bullet"><ListItem>Patients with stage IV salivary gland cancer should be considered candidates for clinical trials.  Their cancer 
may be responsive to aggressive combinations of chemotherapy and radiation. 
Patients with any metastatic lesions could be considered for clinical trials. Chemotherapy
using doxorubicin, cisplatin, cyclophosphamide, and fluorouracil as single
agents or in various combinations is associated with modest response rates.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/> 

</ListItem></ItemizedList><SummarySection id="_TrialSearch_90_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_90_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38950&amp;tt=1&amp;format=2&amp;cn=1">stage IV salivary gland cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_90_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="1651301" MedlineID="91331883">Wang CC, Goodman M: Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 21 (3): 569-76, 1991.</Citation><Citation idx="2" PMID="8407397" MedlineID="94012016">Laramore GE, Krall JM, Griffin TW, et al.: Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27 (2): 235-40, 1993.</Citation><Citation idx="3" PMID="8949764" MedlineID="97107016">Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.</Citation><Citation idx="4" PMID="10208669">Douglas JG, Lee S, Laramore GE, et al.: Neutron radiotherapy for the treatment of locally advanced major salivary gland tumors. Head Neck 21 (3): 255-63, 1999.</Citation><Citation idx="5" PMID="10701733">Douglas JG, Laramore GE, Austin-Seymour M, et al.: Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys 46 (3): 551-7, 2000.</Citation><Citation idx="6" PMID="3884153" MedlineID="85151878">Eisenberger MA: Supporting evidence for an active treatment program for advanced salivary gland carcinomas. Cancer Treat Rep 69 (3): 319-21, 1985.</Citation><Citation idx="7" PMID="3585449" MedlineID="87225120">Venook AP, Tseng A Jr, Meyers FJ, et al.: Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 5 (6): 951-5, 1987.</Citation><Citation idx="8" PMID="196735" MedlineID="77243833">Rentschler R, Burgess MA, Byers R: Chemotherapy of malignant major salivary gland neoplasms: a 25-year review of M. D. Anderson Hospital experience. Cancer 40 (2): 619-24, 1977.</Citation><Citation idx="9" PMID="6754060" MedlineID="83050489">Posner MR, Ervin TJ, Weichselbaum RR, et al.: Chemotherapy of advanced salivary gland neoplasms. Cancer 50 (11): 2261-4, 1982.</Citation><Citation idx="10" PMID="6279995" MedlineID="82172260">Suen JY, Johns ME: Chemotherapy for salivary gland cancer. Laryngoscope 92 (3): 235-9, 1982.</Citation><Citation idx="11" PMID="3114186" MedlineID="87307600">Catterall M, Errington RD: The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy. Int J Radiat Oncol Biol Phys 13 (9): 1313-8, 1987.</Citation><Citation idx="12" PMID="8730718" MedlineID="96295037">Ono M, Watanabe A, Matsumoto Y, et al.: Methamphetamine modifies the photic entraining responses in the rodent suprachiasmatic nucleus via serotonin release. Neuroscience 72 (1): 213-24, 1996.</Citation><Citation idx="13" PMID="3114187" MedlineID="87307601">Saroja KR, Mansell J, Hendrickson FR, et al.: An update on malignant salivary gland tumors treated with neutrons at Fermilab. Int J Radiat Oncol Biol Phys 13 (9): 1319-25, 1987.</Citation><Citation idx="14" PMID="8879381" MedlineID="97033723">Licitra L, Cavina R, Grandi C, et al.: Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 7 (6): 640-2, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_96"><SectMetaData><SpecificDiagnosis ref="CDR0000038951">recurrent salivary gland cancer</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title>Recurrent Major Salivary Gland Cancer</Title><Para id="_97">The prognosis for any treated cancer patient with progressing or relapsing
disease is poor, regardless of cell type or stage.  Selecting further treatment
depends on many factors, including the specific cancer, prior treatment, site
of recurrence, and individual patient considerations.  Fast neutron-beam radiation therapy is  superior to conventional radiation
therapy using x-rays and may be curative in selected patients with  recurrent
disease.<Reference refidx="1"/>  
</Para><Para id="_217">Disease-free survival and overall survival for patients with inoperable,
unresectable, or recurrent malignant salivary gland tumors is superior in
patients treated with fast neutron-beam radiation therapy as compared to those treated with conventional
x-ray radiation therapy.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Clinical trials are appropriate and should be
considered when possible.
 </Para><SummarySection id="_TrialSearch_96_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_96_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38951&amp;tt=1&amp;format=2&amp;cn=1">recurrent salivary gland cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_96_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8407397" MedlineID="94012016">Laramore GE, Krall JM, Griffin TW, et al.: Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 27 (2): 235-40, 1993.</Citation><Citation idx="2" PMID="3114190" MedlineID="87307618">Laramore GE: Fast neutron radiotherapy for inoperable salivary gland tumors: is it the treatment of choice? Int J Radiat Oncol Biol Phys 13 (9): 1421-3, 1987.</Citation><Citation idx="3" PMID="3114187" MedlineID="87307601">Saroja KR, Mansell J, Hendrickson FR, et al.: An update on malignant salivary gland tumors treated with neutrons at Fermilab. Int J Radiat Oncol Biol Phys 13 (9): 1319-25, 1987.</Citation><Citation idx="4" PMID="1571909" MedlineID="92240569">Buchholz TA, Laramore GE, Griffin BR, et al.: The role of fast neutron radiation therapy in the management of advanced salivary gland malignant neoplasms. Cancer 69 (11): 2779-88, 1992.</Citation><Citation idx="5" PMID="8949764" MedlineID="97107016">Krüll A, Schwarz R, Engenhart R, et al.: European results in neutron therapy of malignant salivary gland tumors. Bull Cancer Radiother 83 (Suppl): 125-9s, 1996.</Citation></ReferenceSection></SummarySection><SummarySection id="_120"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (11/7/2014)</Title><Para id="_121">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_418">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062920#_AboutThis_1" url="http://www.cancer.gov/types/head-and-neck/hp/salivary-gland-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of salivary gland cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Salivary Gland Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Scharukh Jalisi, MD, FACS (Boston University Medical Center)</ListItem><ListItem>Eva Szabo, MD (National Cancer Institute)</ListItem><ListItem>Minh Tam Truong, MD (Boston University Medical Center)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Salivary Gland Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/head-and-neck/hp/salivary-gland-treatment-pdq">http://www.cancer.gov/types/head-and-neck/hp/salivary-gland-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2014-11-07</DateLastModified></Summary>
